STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
STUDY  DRUG:  SEL-212 (a combination  of SEL-037 and SEL-110.36)  
STUDY  NUMBER:  SEL-212/202  
VERSION:  3.0 
EFFECTIVE  DATE:  08 Jun 2020  
A STUDY  TO COMPARE  THE  EFFICACY  OF SEL -212 TO KRYSTEXXAÂ® IN GOUT 
PATIENTS REFRACTORY TO CONVENTIONAL THERAPY  
Sponsor  Selecta  Biosciences 
65 Grove Street  
Watertown,  MA 02472,  USA 
Tel:  
Fax:  
Approvers:  
 
 Signature:  Date:  
 
 8June2020  
. on behalf of  
09June2020  NCT #: [STUDY_ID_REMOVED]

PROPRIETARY AND  CONFIDENTIAL  PAGE  2 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
SELECTA  BIOSCIENCES  CLINICAL  STUDY  PROTOCOL  
 
A STUDY  TO COMPARE  THE  EFFICACY  OF SEL -212 TO KRYSTEXXAÂ® IN GOUT 
PATIENTS REFRACTORY TO CONVENTIONAL THERAPY  
STUDY  NUMBER:  SEL -212/202  
 
 
CONTACT  INFORMATION  
 
Sponsor:  Selecta  Biosciences 
65 Grove Street  
Watertown,  MA 02472  
Tel:  
Fax:  
Email:   
Clinical  Study  Leader:   
 
Selecta Biosciences 
65 Grove Street  
Watertown,  MA 02472  
Tel:  
Fax:  
Email:   
Medical  Contact:   
 
Syneos Health 
1030  Sync  Street  
Morrisville,  North  Carolina,  USA  27560 
Tel:  
Email:  
Pharmacovigilance:  Syneos  Health  and Pharmacovigilance 
Fax Number:  
In case of issues with fax, Email: 
 

PROPRIETARY AND  CONFIDENTIAL  PAGE  3 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
 
 
I agree:  INVESTIGATORâ€™S  AGREEMENT  
â€¢ To assume  responsibility for  the proper  conduct  of the study  at this site. 
â€¢ To conduct the study in compliance with applicable regulatory requirements, this protocol, any future 
amendments,  and with any other  study  conduct  procedures  provided  by Selecta  Biosciences.  (Sponsor).  
â€¢ Not to implement  any changes  to the  protocol  without agreement  from the  Sponso r and  prior  review  and 
written approval from the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), 
except  where  necessary  to eliminate  an immediate  hazard  to the patients,  or for administrative  aspects  of 
the study (where permitted by all applicable regulatory requirements).  
â€¢ That I am thoroughly familiar with the appropriate use of the study drug(s), as described in this protocol, 
and any other information  provided  by the Sponsor  including,  but not  limited  to, the following : the current 
Investigatorâ€™s Brochure (IB) or equivalent document, any IB supplement as applicable, or any approved 
product label as applicable.  
â€¢ That I am aware  of, and will comply  with,  â€œgood  clinical  practicesâ€  (GCP)  and all applicable  regulatory 
requirements.  
â€¢ That I  will provide  full and unencumbered  access  to source  documents  and medical  records  needed  for the 
Sponsor, representatives of the Sponsor and regulatory authorities to verify source data and related 
documentation with respect  to this trial.  
â€¢ To ensure  that all persons  assisting  me with the study  are adequately  informed  about  the Sponsor  study 
drug(s) and of their study -related duties and functions as described in the protocol.  
â€¢ That I  have been informed that  certain  regulatory authorities  require  the Sponsor to obtain  and supply, as 
necessary, details about the Investigatorâ€™s ownership interest in the Sponsor or the study drug, and more 
generally  about  his/her  financial  ties with the Sponsor.  The Sponsor  will use and disclose  the information 
solely for the purpose of complying with regulatory requirements.  
 
Hence,  I: 
â€¢ Agree  to supply  Selecta  Biosciences  with any necessary  information  regarding  ownership  interest  and 
financial ties (including those of my spouse and dependent children);  
â€¢ Agree  to promptly  update  this information  if any relevant  changes  occur  during  the course  of the study  and 
for 1 year following completion of the study; and  
â€¢ Agree  that Selecta  Biosciences  may disclose  any information  it has about  such ownership  interests  and 
financial ties to regulatory authorities.  
 
 
 
 
Printed  Name  of Investigator    
Signature of Investigator   Date 
PROPRIETARY AND  CONFIDENTIAL  PAGE  4 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
2. SYNOPSIS  
 
Name of  Sponsor/Company:  
Selecta  Biosciences 
65 Grove Street  
Watertown,  MA 02472,  USA  
Name  of Investigational  Product:  
SEL-212 (a combination  of SEL -037 and SEL-110.36)  
Name  of Comparator  Product: 
KRYSTEXXAÂ® (pegloticase)  
Name  of Active  Ingredient  in Investigational  Product:  
SEL-037 (pegadricase,  recombinant  pegylated  candida  urate  oxidase)  
SEL-110.36  (a nanoparticle  composed  of PLA  [poly{D,L -lactide}]  and PLA -PEG 
[poly{D,L â€”lactide} -block -poly {ethylene -glycol}] encapsulating rapamycin)  
Title  of Study:  
A Study  to Compare  the Efficacy of  SEL-212 to KRYSTEXXAÂ® in Gout  Patients  Refractory 
to Conventional Therapy  
Study  Center(s):  approximately  60 study  centers  in the United States  
Studied  Period  (years):  
Estimated  date first patient  enrolled:  28 February  2019 
Estimated date last patient completed: 31 July 2020  
Objectives:  
Primary:  
â€¢ To assess  the reduction  in serum  uric acid (SUA)  in patients  treated  with SEL-212 
compared to KRYSTEXXAÂ® 
Secondary:  
Secondary  objectives  are to assess  improvement  of the following  parameters  in patients 
treated with SEL -212 compared to KRYSTEXXA:  
â€¢ Gout  flares  
â€¢ SUA  control  
â€¢ Joint  tenderness  and swelling  
â€¢ Quality  of life (QoL)  
Methodology:  
This study  is a randomized, open -label,  parallel -arm study  to compare  the safety and  efficacy 
profiles  of SEL-212 and KRYSTEXXA.  Approximately  150 patients  will be randomized  1:1 
PROPRIETARY AND  CONFIDENTIAL  PAGE  5 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
prior  to Baseline  to receive  treatment  with SEL-212 or KRYSTEXXA  for 6 months. Efficacy 
assessments, as measured by SUA levels, will be conducted at intervals that are appropriate 
to determine treatment effect differences, including at month 3  and month 6. Assessments of 
qualitative endpoints will be conducted on an assessor -blinded basis. Safety will be 
monitored throughout the study.  
Screening  Period  
After providing written informed consent, the patient is considered enrolled in the study. 
Patients will be evaluated for inclusion during the Screening Period. For all patients , the 
standard Screening Period will be up to 45 days prior to Baseline. Concurrently with the 
Screening  Period,  a premedication  period  with colchicine of  at least 7 days prior  to Baseline 
for potential gout flare will be required for all subjects, and a washout period of at least 7 
days will be required prior to Baseline for patients on any urate -lowering therapy (ULT).  
Treatment  Periods  
The total duration  of the treatment  will be 6 months.  Eligible  patients  will be randomized  1:1 
prior to  Baseline to receive SEL -212 or KRYSTEXXA.  
Study  patients  in the SEL-212 arm will receive  study  drug every  28 days coinciding  with 
Day 0 of each Treatment Period for a total of up to 6 infusions of SEL -212. 
Study patients in the KRYSTEXXA arm will receive study drug according to the 
manufacturerâ€™s  prescribing  information, i.e.,  every  14 days coinciding  with Day 0 and Day 14 
of each Treatment Period for a total of up to 12 infusions of KRYSTEXXA.  
Prior to infusion, all patients will receive a standar dized regimen of premedication to 
minimize the potential for infusion reactions during study drug administration. After 
completing  the study  drug infusions,  patients  will remain  at the investigational  site for at least 
1 hour for safety assessments.  
With  each dose,  a blood  sample  will be drawn  for assessment  of SUA  level immediately  prior 
to infusion  (ie, Time 0h)  with SEL-212 or KRYSTEXXA,  and 1 hour after the infusion  of the 
second component of SEL -212 or of KRYSTEXXA is completed. SUA levels will be 
assessed  through  additional  post-infusion  blood  samples at  pre-determined  time points.  Every 
effort will be made to obtain blood samples at the same time of day of each study visit.  
Gout  flares  will be assessed at  every  visit.  QoL and joint swelling  and tenderness  will be 
assessed on Day 0 of Treatment Period 1 and 4, and at the end of Treatment Period 6.  
Assessments  of qualitative  endpoints  (health  questionnaires  and joint assessment)  will be 
conducted on an assessor -blinded basis.  
On dosing  days,  safety  laboratory  samples  will be collected  pre-infusion  and per Schedule  of 
Events in both the SEL -212 arm and the KRYSTEXXA arm. Concomitant medications and 
procedures and adverse events (AEs) will be monitored continuously during the study.  
Follow -Up Period  
Patients will be followed for safety monitoring for 30 (+ 4) days after their final study drug 
infusion and will have an  End of Study visit by telephone. Patients  who terminate the study 
prematurely  will have  all Early  Termination  assessme nts performed.  Patients  who terminate  
PROPRIETARY AND  CONFIDENTIAL  PAGE  6 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
the study  prematurely  who are unable  to be on-site for the Early  Termination  visit will be 
contacted by telephone for safety follow -up. 
Data  and Safety  Monitoring  Committee (DSMC)  
An independent Data and Safety Monitoring Committee (DSMC) will be formed by charter 
to assist  in reviewing  safety data  and may provide  recommendations  to the Sponsor  regarding 
study drug dose adjustment or study termination  
Stopping  Rules  
A patient  will be withdrawn  from  study  drug for meeting  the following  stopping  rule: 
â€¢ In the SEL -212 arm: SUA level > 1.0 mg/dL measured at the Day 21 visit of 
Treatment  Period  1 or SUA  level  > 6.0  mg/dL  at the Day 21 visit of Treatment 
Periods 2, 3, 4, or 5  
â€¢ In the KRYSTEXXA  arm: SUA  level  > 6.0 mg/dL  measured  on 2 consecutive 
pre-dose measurements  
If withdrawn  from  study  drug,  the patient  will continue  study  visits  to the end of Treatment 
Period 6.  
Number  of Patients  (Planned):  
â€¢ Planned  Enrollment:  Approximately  150 patients  randomized  (total):  
o SEL-212: approximately  75 patients  
o KRYSTEXXA:  approximately  75 patients  
Diagnosis  and Main  Criteria  for Inclusion:  
Inclusion  Criteria:  
A patient  must  meet  all of the following  criteria  to be eligible  for this study:  
1. Has provided  written  informed  consent  prior  to the conduct  of any study  specific 
procedures;  
2. Understands  and is willing  and able to comply  with study  requirements,  including  the 
schedule of follow -up visits;  
3. Has a history  of symptomatic  gout defined  as: 
a. â‰¥ 3 gout flares  within 18  months  of Screening or 
b. Presence  of â‰¥ 1 tophus  or 
c. Current diagnosis  of gouty  arthritis  
4. At the Screening  Visit:  male  age 21 â€“ 80 years,  inclusive,  or female of 
non-childbearing  potential  age 21-80 years,  inclusive,  where  non-childbearing 
potential is defined as:  
a. > 6 weeks  after hysterectomy  with or without  surgical  bilateral salpingo - 
oophorectomy or  
PROPRIETARY AND  CONFIDENTIAL  PAGE  7 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
b.  Post-menopausal  (> 24  months  of natural  amenorrhea  or in the absence  of 
> 24 months  of amenorrhea,  1 documented  confirmatory  FSH measurement)  
5. Has at Screening SUA â‰¥ 7 mg/dL, with chronic refractory gout defined as having 
failed  to normalize SUA  and whose signs  and symptoms  are inadequately controlled 
with xanthine  oxidase  inhibitors  at the medically  appropriate  dose,  or these  drugs  are 
contraindicated for the subject;  
6. Is negative  for anti-PEG  antibodies  at Screening;  
7. Has not participated  in a clinical  trial within  30 days of the Screening  Visit  and agrees 
not to participate in a clinical trial for the duration of the study;  
8. Negative  serology  for HIV-1/-2 and negative  antigen  to hepatitis  B and negative 
antibodies to hepatitis C;  
9. Has adequate venous  access  and able to receive IV  therapy;  
10. If applicable,  has sufficiently  recovered  from  any prior  surgery  to allow  for successful 
completion of study procedures.  
 
Exclusion  Criteria:  
A patient  who meets  any of the following  criteria will  be excluded  from this  study:  
1. Prior  exposure  to any experimental  or marketed  uricase  (e.g.,  pegloticase 
[KrystexxaÂ®], pegadricase [SEL -037], rasburicase [Elitek, Fasturtec])  
2. History  of anaphylaxis  or severe  allergic reactions  to medications;  
3. History of any allergy to pegylated products, including, but not limited to, 
peginterferon alfa -2a (PegasysÂ®), peginterferon alfa -2b (PegIntronÂ®), pegfilgrastim 
(NeulastaÂ®), pegaptanib (MacugenÂ®), pegaspargase (OncasparÂ®), pegademase 
(AdagenÂ®), peg -epoetin beta (MirceraÂ®), pegvisomant (SomavertÂ®) certolizumab 
pegol  (CimziaÂ®), nalox egol (MovantikÂ®), peginesatide  (OmontysÂ®), and doxorubicin 
liposome (DoxilÂ®); 
4. Known  moderate  and severe CYP3A4  inhibitors  or inducers  must  be discontinued  
14 days before  dosing  and patients  must  remain  off the medication  for the duration  of 
the study, including natural products such as St. Johnâ€™s Wort or grapefruit juice.  
5. Drugs known to interact with RapamuneÂ® such as cyclosporine, diltiazem, 
erythromycin,  ketoconazole  (and other  antifungals), nicardipine  (and other  calcium 
channel blockers), rifampin, verapamil unless they are stopped 2 weeks prior to 
starting the trial and will not be used during the trial.  
6. Initiation or change in dose of hormone -replacement therapy for menopausal women 
less than 1 month  prior  to the Screening  Visit  or during  the Screening  Phase  would  be 
exclusionary.  If after being on a stable dose of hormone -replacement therapy for  
1 month  the patient  may be considered  for the study  if she continues  to meet  all other 
inclusion and exclusion criteria.  
7. A gout flare during Screening that was resolved for less than 1 week prior to first 
treatment  with study  drug (exclusive  of synovitis/arthritis),  unless  the patient  has a 
history of inter -flare intervals < 1 week.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  8 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
8. Uncontrolled  diabetes  at Screening  with HbA1c  â‰¥ 8%; 
9. Fasting  Screening  glucose >  240 mg/dL  
10. Fasting  Screening  triglyceride >  300 mg/dL;  
11. Fasting  Screening  low-density  lipoprotein  (LDL)  > 200 mg/dL;  
12. Glucose -6-phosphate  dehydrogenase  (G6PD)  deficiency;  
13. Uncontrolled  hypertension  defined  as blood  pressure  >170/100  mmHg  at both 
Screening and 1 week prior to dosing  
14. Individual  laboratory  values  which  are exclusionary  
o White  blood  cell count  (WBC)  < 3.0 x109/L 
o Serum  aspartate  aminotransferase  (AST)  or alanine  aminotransferase 
(ALT) > 3x upper limit of normal (ULN)  
o Estimated  glomerular  filtration  rate (GFR)  < 30 mL/min/1.73  m2 
o Hemoglobin  (Hgb)  < 9 g/dL 
o Serum phosphate < 2.0  mg/dL  
15. Patients  whose arrhythmia  is unstable  on current  treatment;  
16. History  of coronary  artery  disease,  including  myocardial  infarction  or unstable  angina, 
within the last 6 months;  
17. Congestive  heart  failure,  New  York  Heart  Association  Class  III or IV; 
18. Unless  clinically  stable  and/or  appropriately  treated,  electrocardiogram  (ECG)  with 
evidence of prior myocardial infarction, clinically significant arrhythmia, or other 
abnormalities  that, in the opinion  of the investigator,  are consistent  with significant 
underlying cardiac disease;  
19. History  of signif icant  hematological  disorders  or autoimmune  disorders,  and/or 
subject is immunosuppressed or immunocompromised;  
20. Subject  is currently  taking  dabigatran  (PradaxaÂ®), rivaroxaban  (XareltoÂ®), 
edoxaban (SavaysaÂ®), warfarin (CoumadinÂ®), or apixaban (EliquisÂ®); 
21. Subject has received an inactivated vaccine in the previous 3 months with respect to 
the randomization date or has received a live virus vaccine in the previous 6 months 
with respect  to the randomization  date.  Recombinant  vaccines  are excluded  from  this 
exclusion criterium.  
22. Subject  is planning  to receive  any live or attenuated  virus  vaccination  during  the 
study.  
23. History  of malignancy  within  the last 5 years  other  than basal  skin cancer;  
24. Any condition,  that in the opinion  of the investigator,  would  be negatively  affected  by 
rapamycin.  
25. Subjects  with a documented  history  of moderate  or severe  alcohol  or substance  use 
disorder within the 12 months prior to randomization.  
26. Subjects  who,  in the opinion  of the investigator,  present  with a condition  that would 
compromise their safety or that would make study completion unlikely.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  9 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Investigational  Product  and Comparator  Product,  Dosage  and Mode  of Administration:  
INVESTIGATIONAL  PRODUCT  
â€¢ SEL-212 is  comprised  of 2 components:  SEL-110.36 and  SEL-037 
o SEL-110.36:  nanoparticle  composed  of PLA  and PLA -PEG encapsulating 
rapamycin for reconstitution with sterile water for injection.  
o SEL-037: pegadricase,  a recombinant  pegylated  candida  urate  oxidase. 
Dosage of Investigational Drug  
â€¢ SEL-110.36:  calculation  based  on patientâ€™s  body  weight  
o 0.15 mg/kg  
â€¢ SEL-037: calculation  based  on patientâ€™s  body  weight  
o 0.2 mg/kg  
Mode  of Administration  (SEL -212) 
â€¢ Premedication  for SEL-212 (prior  to study  drug administration)  
o Colchicine  0.6 mg oral (PO)  every  day starting  at least 7 days prior  to Day 0 
â–ª Patients not already taking colchicine will receive colchicine 1.2 mg as a 
single  loading  dose followed  by the 0.6 mg every  day regimen.  If the patient 
cannot  tolerate  the loading  dose level  of 1.2 mg, then the patient  will initiate 
and maintain colchicine at 0.6 mg.  
o Prednisone  40 mg oral  (PO)  approximately  24 (Â± 12) hours  
o Fexofenadine 180  mg oral  (PO) approximately  12 (Â±  2) hours  
o Fexofenadine 180  mg oral  (PO) approximately  2 (Â± 1) hours  
o Methylprednisolone 40 mg  (or equivalent)  IV approximately 1  (Â± 0.5) hours  
â€¢ SEL-110.36  
o IV infusion  with a syringe  infusion  pump  at a steady  rate of 3.0 mL/hr  for the first 
30 minutes, then a rate sufficient to deliver the remaining dose volume over a 
period of 60 minutes concurrently with normal saline  
â€¢ SEL-037 
o Administration  initiated within  15 minutes  after completion  of the SEL-110.36 
infusion.  
o Administered  via infusion  pump  over a time period  of no less than 120 minutes. If 
an infusion reaction occurs during the administration of SEL -037, the infusion 
may be slowed, or stopped and restarted at a slower rate at the discretion of the 
physician.  
KRYSTEXXA  
â€¢ Premedication  for KRYSTEXXA  (prior  to study  drug administratio n) 
o Colchicine  0.6 mg oral (PO)  every  day starting  at least 7 days prior  to Day 0 
PROPRIETARY AND  CONFIDENTIAL  PAGE  10 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
â–ª Patients not already taking colchicine will receive colchicine 1.2 mg as a 
single  loading  dose followed  by the 0.6 mg every  day regimen.  If the patient 
cannot  tolerate  the loading  dose level  of 1.2 mg, then the patient  will initiate 
and maintain colchicine at 0.6 mg.  
o Prednisone  40 mg oral (PO)  approximately  24 (Â± 12) hours  
o Fexofenadine 180  mg oral  (PO)  approximately 12  (Â± 2) hours  
o Fexofenadine 180  mg oral  (PO) approximately  2 (Â± 1) hours  
o Methylprednisolone 40 mg  (or equivalent)  IV approximately 1  (Â± 0.5) hours  
â€¢ KRYSTEXXA (pegloticase injection) will consist of commercially available study 
drug administered  at a dosage of  8 mg (uricas e protein)  given  as an IV infusion  every 
2 weeks, consistent with the manufacturerâ€™s currently approved labeling 
(KRYSTEXXA Prescribing Information 2018 ). 
Duration  of Treatment:  
All patients  are planned  to receive  study  drug during  6 months  of treatment.  The SEL-212 
treatment arm will receive a total of up to 6 infusions, scheduled every 28 days. The 
KRYSTEXXA treatment  arm will receive a total of up to 12 infusions, scheduled every  
14 days,  according  to the manufacturerâ€™s  currently  approved  label  (KRYSTEXXA  Prescribing  
Information 2018 ). 
The total duration  of participation  in the study  will range  from  approximately 26  to 31 weeks 
(184 to 219 days) for patients randomized to SEL -212 and approximately 28 to 33 weeks 
(198 to 233 days) for patients randomized to KRYSTEXXA as follows:  
â€¢ Screening  and/or  washout  and premedication  period:  up to 45 days (up to 6.5 weeks)  
â€¢ Treatment:  168 days (24 weeks)  for SEL-212 and KRYSTEXXA  
â€¢ Safety  Follow -Up: 30 (+ 4) days after the  date of last  infusion  
o SEL-212: Last scheduled  infusion  on Study  Day 140 
o KRYSTEXXA:  Last schedule  infusion  on Study  Day 154 
Criteria  for Evaluation:  
Efficacy:  
Primary Endpoint : 
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve 
and maintain reduction of SUA < 6 mg/dL for at least 80% of the time during 
Treatment Period 3 and Treatment Period 6  
Secondary  Endpoints : 
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve 
and maintain reduction of SUA < 6 mg/dL for at least 80% of the time during 
Treatment Period 6  
PROPRIETARY AND  CONFIDENTIAL  PAGE  11 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve 
and maintain reduction of SUA < 6 mg/dL for 100% of the time during Treatment 
Period 6  
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve 
and maintain reduction of SUA < 6 mg/dL for at least 80% of the time during 
Treatment Period 3  
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve 
and maintain reduction of SUA < 6 mg/dL for 100% of the time during Treatment 
Period 3  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  in pre-dose SUA  values  
> 6 mg/dL during Treatment Periods 2 -6. The pre -dose SUA is collected on the 
dosing day prior to the dosing administration or it is collected at the visit where 
dosing  would  have  occurred  had the patient  not been  previously  withdrawn  from 
study drug.  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  in health 
questionnaires  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of gout flare incidence 
per 3 -month period (Treatment Periods 1 -3 and Treatment Periods 4 -6) 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of gout flare frequency 
per 3 -month period (Treatment Periods 1 -3 and Treatment Periods 4 -6) 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  from 
Baseline to Treatment Period 6 in number of tender joints  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  from 
Baseline to Treatment Period 6 in number of swollen joints  
Safety:  
Safety Endpoints : 
â€¢ Safety  and tolerability  of SEL-212 compared  to KRYSTEXXA  as assessed  by AEs, 
serious AEs (SAEs), deaths, and discontinuations due to AEs  
â€¢ Additional  safety  assessments  will include  review  and evaluation  of laboratory  testing 
including hematology, coagulation, chemistry, urinalysis; vital signs; 12 -lead ECGs; 
and physical examination findings.  
Statistical  Methods  
Details of the statistical methods outlined in the protocol for this study, including the 
hierarchical  ordering  of the secondary  endpoints,  will be documented  in a Statistical  Analysis 
Plan (SAP) that wil l be finalized prior to first patient randomized. The SAP may add 
additional exploratory analyses; modifications to the planned analyses will be identified as 
such in the SAP.  
Analysis  Populations  
PROPRIETARY AND  CONFIDENTIAL  PAGE  12 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
â€¢ Screened  / Randomized  Set: The Screened  Set will include  all patients  who signed  an 
informed consent. The Randomized Set will include all patients randomized.  
â€¢ Safety  Set (SS):  The Safety  Set will include  all patients  who were  administered  any 
amount of study medication. Patients will be  analyzed according to treatment 
received.  The SS will be used for all analyses of safety endpoints and for the 
presentation of patients in all patient listings.  
â€¢ Intent -to-Treat  (ITT)  Set: The Intent -to-Treat  (ITT)  Set will be used as the primary 
population for the analysis of efficacy.  The ITT Set will include all randomized 
patients. Patients will be analyzed according to randomized treatment.  
â€¢ Modified  ITT (mITT)  Set: The modified  ITT (mITT)  Set will  include  all randomized 
patients who were admin istered at least one complete dose of study medication and 
have at least one post -baseline assessment of SUA. Patients will be analyzed 
according to randomized treatment. The mITT will also be used for analyses of 
efficacy endpoints.  
â€¢ Per Protocol (PP) Set: The Per Protocol Set (PPS) will include all patients who 1) 
were administered any amount of study medication, and 2) have completed at least 
65% of the study  dosing  visits  with or without  receiving  study  drug (eg at least 4 of 6 
TP Day 0 visits  for patients  receiving SEL -212 or at least 8 of 12 TP Day 0  or Day14 
visits for patients receiving Krystexxa) unless early termination from the study 
occurred after study drug withdrawal due to meeting stopping rules or due to an 
adverse event, or due to PI di scretion (for example where at least one pre -dose SUA 
was >6 mg/dL in the Krystexxa arm and patient was discontinued from study 
treatment), and 3) who have no major Protocol deviations affecting the primary 
efficacy assessments. Patients will be analyzed a ccording to randomized treatment.  
 
Efficacy Analyses  
Primary  Efficacy  Analysis  
The primary  estimand  will take into consideration  the treatment  policy  strategy,  ie, Treatment 
Period 6 (and also Treatment Period 3) assessments will be considered  for all subjects in ITT 
independently whether the subject has completed the study treatment or has terminated early 
the study treatment. Additionally, the estimand based on the while -on-treatment strategy for 
dealing with study treatment terminators will b e defined. For all used estimands of the 
primary  efficacy,  the estimator  for the comparison  between  the treatment  groups  is defined  as 
the difference in the proportion of responders between subjects receiving SEL -212 versus 
those receiving KRYSTEXXA during  Treatment Periods 3 and 6. The statistical testing will 
be performed  confirmatory  using  the Cochran -Mantel -Haenszel  (CMH)  test â€“ considering  the 
randomization stratum of tophus presence (yes/no) â€“ with a one -sided type 1 error rate  
Î± = 5%. In addition,  90% two-sided  confidence  intervals  for the overall  treatment  difference 
between SEL -212 and KRYSTEXXA treatment groups without stratification will be 
computed. The analysis of the estimands  will be carried out based on the ITT primarily.  
Supportive  analyses  will be performed  on the mITT  and the PP. For each defined  estimand 
sensitivity analyses will be performed using different imputation approaches for missing 
values. Details  of the  applied  approaches  will be presented in  the Statistical Analysis Plan.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  13 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
The SUA time curve will be used to estimate the proportion of time that the SUA level is 
below 6 mg/dL. Based on the serum samples collected during Treatment Periods 3 and 6, an 
estimate of the time with SUA < 6 mg/dL can be determined by connecting each two 
neighboring data points with a straight line. If the SUA time curve goes above 6 mg/dL the 
linear interpolation method will be used to estimate the point in time at which t he SUA time 
curve  intercepts  the line between  the last SUA  value  < 6 mg/dL  and the first value  â‰¥ 6 mg/dL.  
The proportion  of time that the SUA  level  is < 6 mg/dL will  be computed  by taking  the ratio 
between the time during which the SUA level remains < 6 mg/dL (if necessary, using the 
linear interpolation method) and the entire time interval within Treatment Periods 3 and 6.  
Let T1 be the total time interval in hours for Treatment Period 3 of which W1 hours is the 
time interval during which SUA level is < 6 mg/dL. Similarly, for Treatment Period 6, 
assume T2 is the total time interval in hours of which W2 hours is the time interval during 
which SUA level is < 6 mg/dL. For a subject to be considered a responder, the proportion of 
time that the SUA  level  is < 6 mg/dL  during  Treatment  Periods  3 and 6 must  be at least 80%. 
The proportion of time that the SUA level is < 6 mg/dL, i.e., percentage of non - 
hyperuricemic time, is calculated using the following formula:  
ð‘Š1 + ð‘Š2 
ð‘ƒð‘Ÿð‘œð‘ð‘œð‘Ÿð‘¡ð‘–ð‘œð‘›  = ð‘‡1 + ð‘‡2 Ã— 100  
A logistic  regression  model  controlling  for the distribution  of baseline  characteristics  will be 
performed as supportive analysis.  
Summary  tables  of the percentage  of responder  (subjects  who achieve  and maintain  reduction 
of SUA < 6 mg/dL for at least 80% of the time)  in each treatment period will be provided by 
treatment group. Additionally,  a summary table with the total time a subject has SUA values  
< 6 mg/dL  will be provided  for each treatment  period  by treatment  group.  
Summary tables of the actual values and change from baseline for SUA results will be 
provided for each scheduled sampling time point by treatment group. Additionally, mean 
SUA  level,  reduction  in mean SUA  and percent  reduction  in mean SUA  from  baseline  during 
Treatment Period 3 or Treatment Period 6 will be presented by treatment group.  
Secondary Efficacy  Analyses  
All statistical tests in secondary endpoints for the comparison between SEL -212 and 
KRYSTEXXA will be performed using one -sided tests at a type 1 error rate level of  Î±=5%. 
In addition, 90% confidence intervals for treatment differences between SEL -212 and 
KRYSTEXXA  treatment  groups  will be computed.  The efficacy  analyses  will be carried  out 
based on the IT T and PP Sets. mITT analyses will be performed if appropriate.  
For assessment of SUA in the secondary efficacy analyses, summary tables of the number 
and percentage of subjects for each endpoint will be presented by  treatment group, and the 
comparison  betw een the treatment  groups  will be performed  similar  to the primary  efficacy 
endpoint using a CMH -test considering the randomization stratum.  
For the health  questionnaires,  comparison  with regards  to change  from  baseline  in health  
questionnaires will be performed using an ANCOVA with the respective change from 
baseline  value  as dependent  variable,  treatment  group and  the randomization  stratum  as 
PROPRIETARY AND  CONFIDENTIAL  PAGE  14 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
independent fixed factors and the baseline value as independent covariate. For each health 
questionnaire, summary tables of total scores or domain scores and subscale scores will be 
provided  for each scheduled  assessment  time by treatment  group. Additionally,  summaries  of 
the changes from baseline will be p rovided.  
The number and percentage of subjects reporting gout flares per 3 -months period, i.e. 
Treatment Periods 1 to 3 and Treatment Periods 4 to 6, will be summarized by treatment 
group and will be tested using a CMH -test considering the randomization st ratum. The 
frequency  of gout flares  will be summarized  per 3-months  period,  i.e. for Treatment  Periods  1 
to 3 and Treatment Periods 4 to 6 for each treatment and will be compared using ANOVA 
considering the randomization stratum and treatment as fixed factors.  
Comparison with regards to change of tender joints and swollen joints from baseline will be 
performed using an ANCOVA with the change from baseline value as dependent variable, 
treatment group and randomization stratum as independent fixed factors  and the baseline 
number of tender joints and swollen joints as independent covariates, respectively. In case of 
non-normality,  the non-parametric  Wilcoxon  test will be used for the comparison  between  the 
treatment groups. Summary tables of the number of t ender joints and swollen joints for each 
assessment timepoint and for the change from baseline will be provided by treatment group, 
respectively.  
A subgroup analysis will be conducted for patients who receive â€œadditional gout flare 
treatmentâ€  in each arm for these objectives.  Details  of this subgroup  analysis  will be provided 
in the SAP.  
Safety  Analyses  
All AEs will be coded  and grouped  into Preferred  Terms  (PT) by System  Organ  Class  (SOC), 
using the most recent MedDRA Version. All AEs will be summarized by SOC and PT. An 
overall  summary  will be provided  of the number  and percentage of  patients in  each treatment 
group (SEL -212 and KRYSTEXXA) reporting TEAEs, serious TEAEs, treatment -related 
TEAEs, AESIs, TEAEs leading  to withdrawal and TEAEs lea ding to death. The number and 
percentage of patients with TEAEs /serious TEAEs / AESIs / TEAEs leading to withdrawal / 
treatment -related TEAEs will be summarized by SOC and PT for each treatment group  
(SEL -212 and KRYSTEXXA).  TEAEs  will also be summarized  by maximum  intensity  and 
causality.  
Laboratory  data will be summarized  by the type of laboratory  test and will be presented  for 
each scheduled visit stratified by treatment group (SEL -212 and KRYSTEXXA). Normal 
reference ranges  and markedly abno rmal results  will be used  in the summary of laboratory 
data. Data will be flagged according to the reference limits (High or Low), if applicable.  
Changes from baseline will be presented for each post -baseline visit. Shift tables of the 
number of patients w ith low/normal/high values at each scheduled post -baseline visit 
compared  to the low/normal/high  categorization  at baseline  will be provided  by treatment 
group (SEL -212 and KRYSTEXXA).  
Summary  tables  of the actual  values  and changes  from  baseline  will be provided  for each 
vital sign parameter at each scheduled visit by treatment group (SEL -212 and 
KRYSTEXXA).  
PROPRIETARY AND  CONFIDENTIAL  PAGE  15 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
For each 12 -lead ECG variable the actual value and the change from baseline will be 
summarized  for the scheduled  visits  by treatment  group (SEL -212 and KRYSTEXXA).  
Frequency tables of abnormal clinically significant evaluations as well as the number and 
percentage  of patients  with noteworthy  QTcF/QTcB  values  (> 450,  > 480 and > 500 ms) and 
of patients  with noteworthy  QTcF/QTcB  changes  from  baseline  (â‰¥ 30 but <60; â‰¥ 60 ms)  will 
be provided.  
Sample  Size Determination  
The primary efficacy criterion in this study is defined as the percentage of subjects who 
achieve and maintain reduction of SUA < 6 mg/dL for at least 80% of the time  during 
Treatment Period 3 and Treatment Period 6. The percentage of responders according to the 
above criterion is assumed to be 65% in the SEL -212 arm and 44% in the KRYSTEXXA 
arm. Using the Chi -square test for comparison between the SEL -212 arm and the 
KRYSTEXXA arm, and considering a one -sided Î±=5% and the statistical power of 80%, 
results in 69 subjects per treatment group. Taking into account that some subjects may be 
excluded from the mITT analyses, 75 subjects per treatment group will be randomized.  For 
the sample size estimation, Chi -square test, instead of the Cochran -Mantel -Haenszel test, is 
used although  the randomization  will be stratified  for tophus  presence  (yes/no)  as there  is no 
valid assumption of the distribution of this stratification variable within the eligible subject 
population.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  16 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
3. TABLE  OF CONTENTS,  LIST  OF TABLES,  AND  LIST  OF FIGURES  
TABLE  OF CONTENTS  
1. TITLE  PAGE  ................................ ................................ ................................ ..........................  1 
2. SYNOPSIS  ................................ ................................ ................................ ...............................  4 
3. TABLE  OF CONTENTS,  LIST  OF TABLES,  AND  LIST  OF FIGURES  .....................  16 
4. LIST  OF ABBREVIATIONS  AND  DEFINITIONS  OF TERMS  ................................ ... 20 
5. INTRODUCTION  ................................ ................................ ................................ ................  23 
5.1 Gout  and Refractory Gout  ................................ ................................ ..........................  23 
5.2 Symptoms  of Gout  ................................ ................................ ................................ ...... 23 
5.3 Gout  and Hyperuricemia:  Exacerbation  of Existing  Comorbidities  ...........................  24 
5.4 Impact  on Quality of  Life ................................ ................................ ...........................  24 
5.5 Approved   Therapies   for  Chronic   Gout   Refractory   to  Conventional  
Therapy  ................................ ................................ ................................ .......................  25 
5.6 Unmet  Medical  Need  ................................ ................................ ................................ .. 26 
6. STUDY  OBJECTIVES  AND ENDPOINTS  ................................ ................................ ....... 28 
6.1 Study  Objectives  ................................ ................................ ................................ .........  28 
6.1.1 Primary Objective  ................................ ................................ .....................  28 
6.1.2 Secondary  Objectives  ................................ ................................ ...............  28 
6.2 Study  Endpoints  ................................ ................................ ................................ ..........  28 
6.2.1 Primary Endpoint  ................................ ................................ ......................  28 
6.2.2 Secondary  Endpoints  ................................ ................................ ................  28 
6.2.3 Safety Endpoints  ................................ ................................ .......................  29 
7. INVESTIGATIONAL  PLA N ................................ ................................ ..............................  30 
7.1 Overall Study Design ................................ ................................ ................................ .. 30 
7.1.1 Screening  Period  ................................ ................................ .......................  30 
7.1.2 Treatment  Period  ................................ ................................ ......................  30 
7.1.3 Follow -Up Period  ................................ ................................ .....................  31 
7.2 Number  of Patients  ................................ ................................ ................................ ..... 31 
7.3 Treatment  Assignment  ................................ ................................ ................................  31 
7.4 Dose  Adjustment  Criteria  ................................ ................................ ...........................  32 
7.4.1 Safety  Criteria  for Adjustment  or Stopping  Doses  ................................ ... 32 
7.4.1.1  SEL-212 ................................ ................................ .............  32 
7.4.1.2  KRYSTEXXA  ................................ ................................ ... 32 
7.4.2 Criteria  for Adjustment  or Stopping  Doses  ................................ ..............  33 
7.5 Criteria  for Study  Termination  ................................ ................................ ...................  33 
7.6 Study  Rationale  ................................ ................................ ................................ ...........  33 
7.6.1 Rationale  for the Study  Design  ................................ ................................ . 33 
7.6.2 Rationale  for the Study  Population  ................................ ...........................  34 
7.6.3 Rationale  for the Selected  Dose  ................................ ................................  34 
7.6.3.1  Phase  1b Study  with SEL-212 ................................ ...........  34 
7.6.3.2  Phase  2 Study  with SEL-212 ................................ .............  35 
7.6.4 Rationale  for the Primary  Efficacy  Endpoint ................................ ............  35 
7.6.5 Rationale  for Secondary  Efficacy  Endpoints  ................................ ............  36 
7.7 Benefits  and Risks  ................................ ................................ ................................ ...... 36 
8. SELECTION  AND  WITHDRAWAL  OF PATIENTS  ................................ .....................  37 
PROPRIETARY AND  CONFIDENTIAL  PAGE  17 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 8.1 Patient  Inclusion  Criteria  ................................ ................................ ............................  37 
8.2 Patient  Exclusion  Criteria  ................................ ................................ ...........................  37 
8.2.1 Patient Completion  and Withdrawal  Criteria  ................................ ............  39 
8.2.1.1  Screen  Failures  ................................ ................................ ... 39 
8.2.1.2  Patient Completion  ................................ .............................  39 
8.2.1.3  Enrolled  Patient  Withdrawal  and 
Discontin uations  ................................ ................................ . 39 
9. TREATMENT  OF PATIENTS  ................................ ................................ ...........................  41 
9.1 Description  of Study  Drug  ................................ ................................ ..........................  41 
9.2 Concomitant  Medications  and Therapies  ................................ ................................ ... 41 
9.2.1 Uric Acid Lowering  Therapy  ................................ ................................ .... 41 
9.2.2 Anticoagulants  Use ................................ ................................ ...................  42 
9.2.3 Hormone  Replacement  Therapy  ................................ ...............................  42 
9.2.4 CYP3A4  Inducers  and Inhibitors  ................................ ..............................  42 
9.2.5 Other  Concomitant  Medications  ................................ ...............................  42 
9.3 Treatment  Compliance  ................................ ................................ ................................  42 
9.4 Randomization  and Blinding  ................................ ................................ ......................  42 
10. STUDY  DRUG  MATERIALS  AND  MANAGEMENT  ................................ ....................  43 
10.1 Study  Drug  ................................ ................................ ................................ ..................  43 
10.1.1  SEL-212 ................................ ................................ ................................ .... 43 
10.1.2  KRYSTEXXA  ................................ ................................ ..........................  43 
10.2 Study  Drug Packaging  and Labeling  ................................ ................................ ..........  43 
10.3 Study  Drug  Storage ................................ ................................ ................................ ..... 43 
10.4 Study Drug  Preparation  ................................ ................................ ..............................  43 
10.4.1  SEL-037 Preparation ................................ ................................ .................  44 
10.4.2  SEL-110.36  Preparation ................................ ................................ ............  44 
10.4.3  KRYSTEXXA  Preparation  ................................ ................................ ....... 44 
10.5 Premedication  ................................ ................................ ................................ .............  45 
10.5.1  Gout  Flares  (Prevention  and Treatment) ................................ ...................  45 
10.5.2  Premedication  with Antihistamines  and Steroids  ................................ ..... 45 
10.6 Administration  ................................ ................................ ................................ ............  46 
10.6.1  SEL-212 ................................ ................................ ................................ .... 46 
10.6.2  KRYSTEXXA  ................................ ................................ ..........................  46 
10.7 Study  Drug  Accountability  ................................ ................................ .........................  47 
10.8 Study  Drug  Handling  and Disposal  ................................ ................................ ............  47 
11. ASSESSMENT  OF EFFICACY  ................................ ................................ ..........................  48 
11.1 Activity  Assessment  ................................ ................................ ................................ ... 48 
11.1.1  Serum Uric  Acid Assessment  ................................ ................................ ... 48 
11.2 Gout  Assessment ................................ ................................ ................................ .........  48 
11.2.1  Gout  Flare Assessment  ................................ ................................ .............  48 
11.2.2  Joint  Assessment  ................................ ................................ .......................  48 
11.3 Health  Questionna ires: Patient  Reported  Outcomes  and Quality  of Life 
Assessment  ................................ ................................ ................................ .................  48 
11.3.1  Health  Assessment  Questionnaire -Disability  Index  (HAQ -DI)................  48 
11.3.2  Provider  Global  Assessment  of Disease  Activity  ................................ ..... 48 
11.3.3  Short  Form Health  Survey  36 (SF-36)................................ ......................  49 
PROPRIETARY AND  CONFIDENTIAL  PAGE  18 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 12. ASSESSMENT  OF SAFETY ................................ ................................ ...............................  50 
12.1 Safety Parameters  ................................ ................................ ................................ ....... 50 
12.1.1  Demographic/Medical  History  ................................ ................................ . 50 
12.1.2  Concomitant  Medications  and Procedures ................................ ................  50 
12.1.3  Vital  Signs  ................................ ................................ ................................  50 
12.1.4  Electrocardiogram  (ECG)  ................................ ................................ .........  50 
12.1.5  Weight  and Height  ................................ ................................ ....................  50 
12.1.6  Physical  Examination  ................................ ................................ ...............  50 
12.1.7  Tophus  Assessment ................................ ................................ ...................  50 
12.1.8  Laboratory  Assessments  ................................ ................................ ...........  50 
12.1.8.1  Hematology  ................................ ................................ ........  51 
12.1.8.2  Blood Chemistry  ................................ ................................  51 
12.1.8.3  Lipids  ................................ ................................ .................  51 
12.1.8.4  Coagulation  ................................ ................................ ........  51 
12.1.8.5  Urinalysis  ................................ ................................ ...........  51 
12.1.8.6  Anti-Drug -Antibodies  ................................ ........................  51 
12.1.8.7  Serology  ................................ ................................ .............  51 
12.1.8.8  Pregnancy  Screen  ................................ ...............................  51 
12.1.8.9  Definition  of Childbearing  Potential  and 
Acceptable  Contraceptive  Methods  ................................ ... 52 
12.1.9  Premedication  Regimen  ................................ ................................ ............  53 
12.2 Adverse  and Serious  Adverse Events  ................................ ................................ .........  53 
12.2.1  Definition  of Adverse  Events  ................................ ................................ ... 53 
12.2.1.1  Adverse  Event (AE)  ................................ ...........................  53 
12.2.1.2  Serious Adverse  Event (SAE)  ................................ ............  53 
12.2.1.3  Suspected  Adverse  Reaction  ................................ ..............  53 
12.2.1.4  Unexpected  Adverse  Events  and Unexpected  
Suspected  Drug  Reaction  ................................ ...................  54 
12.2.1.5  Infusion  Reactions  / Adverse  Events  of Special  
Interest ................................ ................................ ................  54 
12.2.2  Recording Adverse  Events  ................................ ................................ ....... 55 
12.2.2.1  Adverse  Event Term/Name/Description  ............................  55 
12.2.2.2  Relationship  to Study  Drug  ................................ ................  55 
12.2.2.3  Adverse  Event  Intensity/Severity  Grading .........................  56 
12.2.2.4  Assessment  of Outcome  ................................ .....................  56 
12.2.2.5  Action  Taken  with Study  Drug  ................................ ..........  57 
12.2.2.6  Laboratory  and Diagnostic  Abnormalities  as 
Adverse  Events  ................................ ................................ .. 57 
12.2.2.7  Pregnancy  ................................ ................................ ...........  57 
12.2.3  Reporting  Adverse  Events  ................................ ................................ ........  58 
12.2.3.1  Adverse  Event  Reporting  Period  ................................ ....... 58 
12.2.3.2  SAE Reporting  Procedures  ................................ ................  58 
12.2.3.3  Regulatory  Reporting  Requirements  for SAEs  ..................  59 
12.2.3.4  Reporting  Safety  Information  to the IRB/IEC  ...................  59 
12.2.4  Follow -up of Adverse  Events  ................................ ................................ ... 59 
13. STATISTICS  ................................ ................................ ................................ .........................  61 
PROPRIETARY AND  CONFIDENTIAL  PAGE  19 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 13.1 Sample  Size Determination ................................ ................................ .........................  61 
13.2 Analysis  Populations  ................................ ................................ ................................ ... 61 
13.2.1  Screened  / Randomized  Set ................................ ................................ ...... 61 
13.2.2  Safety  Set (SS) ................................ ................................ ..........................  61 
13.2.3  Intent -to-Treat (ITT)  Set ................................ ................................ ...........  61 
13.2.4  Modified  ITT (mITT)  Set ................................ ................................ .........  62 
13.2.5  Per Protocol Set ................................ ................................ ........................  62 
13.3 Protocol Deviations  ................................ ................................ ................................ .... 62 
13.4 Efficacy  Analyses  ................................ ................................ ................................ ....... 62 
13.4.1  Primary  Efficacy  Endpoint  ................................ ................................ ....... 62 
13.4.2  Secondary  Efficacy  Endpoints  and Analyses  ................................ ...........  64 
13.4.3  Subgroup  Analyses  ................................ ................................ ...................  66 
13.5 Safety Analyses  ................................ ................................ ................................ ..........  66 
13.5.1  Extent  of exposure  ................................ ................................ ....................  66 
13.5.2  Adverse  Events  / Adverse Drug  Reactions  ................................ ...............  66 
13.5.3  Laboratory  Assessments  ................................ ................................ ...........  66 
13.5.4  Vital  Signs  ................................ ................................ ................................  67 
13.5.5  ECG  ................................ ................................ ................................ ..........  67 
14. DIRECT  ACCESS  TO SOURCE  DATA/DOCUMENTS ................................ .................  68 
15. QUALITY  CONTROL  AND  QUALITY  ASSURANCE  ................................ ..................  69 
15.1 Study  Monitori ng ................................ ................................ ................................ ........  69 
15.2 Audits  and Inspections  ................................ ................................ ................................  69 
15.3 Protocol Modifications  ................................ ................................ ...............................  69 
16. ETHICS  AND  GOOD  CLINICAL  PRACTICE  COMPLIANCE  ................................ ... 70 
17. DATA  HANDLING  AND  RECORDKEEPING  ................................ ................................  71 
17.1 Data Management  ................................ ................................ ................................ ....... 71 
17.1.1  Case  Report  Forms  ................................ ................................ ...................  71 
17.1.2  Retention  of Records  ................................ ................................ ................  71 
18. REPORTING  STUDY  RESULTS  AND  PUBLICATION  POLICY  ...............................  73 
19. LIST  OF REFERENCES  ................................ ................................ ................................ ..... 74 
20. APPENDICES  ................................ ................................ ................................ .......................  77 
APPENDIX  A SCHEDULE  OF ASSESSMENTS  FOR  PATIENTS  
RANDOMIZED  TO SEL -212................................ ................................ .........  78 
APPENDIX  B SCHEDULE  OF ASSESSMENTS:  SEL -212 DOSING  AND  
SUA  DURING  THE  TREATMENT  PERIOD  ................................ .............  80 
APPENDIX  C SCHEDULE  OF ASSESSMENTS  FOR  PATIENTS  
RANDOMIZED  TO KRYSTEXXA  ................................ ..............................  81 
APPENDIX  D SCHEDULE  OF ASSESSMENTS:  KRYSTEXXA  DOSING  
AND  SUA  DURING  THE  TREATMENT  PERIOD  ................................ .... 83 
LIST  OF IN-TEXT  TABLES  
Table  1: Investigational  Product  ................................ ................................ ................ 41 
LIST  OF IN-TEXT  FIGURES  
Figure  1: Study  Schematic  ................................ ................................ .......................... 31 
PROPRIETARY AND  CONFIDENTIAL  PAGE  20 OF 84 STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
4. LIST  OF ABBREVIATIONS  AND  DEFINITIONS  OF TERMS
Abbreviation  or Specialist  Term  Definition  or Explanation  
AE adverse  event  
ALT  alanine aminotransferase  
ANCOVA  analysis  of covariance  
aPTT  activated  partial  thromboplastin  time 
AST aspartate aminotransferase  
BUN  blood urea  nitrogen  
CFR Code  of Federal  Regulations  
cm centimeter  
CR Complete  Response  
CRF case report  form  
CRO  contract  research organization  
CT computed  tomography  
CYP3A4  Cytochrome  P450,  family  3, subfamily  A 
d day 
dL deciliter  
DSMC  Data  and Safety  Monitoring  Committee  
EC Ethics Committee  
ECG  electrocardiogram  
eCRF  electronic  case report form  
EEA  European  Economic Area  
EOS End-of-Study  
ET Early  Termination  
FAAN  Food  Allergy  & Anaphylaxis  Network  
FAS Full Analysis  Set 
FSH Follicle  Stimulating  Hormone  
G6PD  glucose -6-phosphate  dehydrogenase  
GCP  Good  Clinical  Practice  
GFR  glomerular  filtration  rate 
h hour 
HAQ -DI Health  Assessment  Questionnaire -Disability  Index  
HbA1c  hemoglobin  A1c 
HBsAg  hepatitis -B surface  antigen  
hCG human  chorionic gonadotropin  
Hct hematocrit  
HCVAb  hepatitis -C antibody  
HDL  high density lipoprotein  
Hgb hemoglobin  
PROPRIETARY AND  CONFIDENTIAL  PAGE  21 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Abbreviation  or Specialist  Term  Definition  or Explanation  
HIV human  immunodeficiency  virus  
I Improved  
ICF informed  consent  form  
ICH International  Conference  on Harmonisation  
IEC International  Ethics  Committee  
IND investigational  new drug 
INR international  normalized  ratio 
IRB Institutional  Review  Board  
ITT Intent  to Treat  
IUD intrauterine  device  
IUS intrauterine  hormone  releasing  system  
IV intravenous  
kg kilogram  
LDL  low-density  lipoprotein  
MCH  mean  corpuscular  hemoglobin  
MCHC  mean  corpuscular  hemoglobin  concentration  
MCV  mean  corpuscular  volume  
mg milligram  
mmHg  millimeters  of mercury  
MPV  mean  platelet  volume  
MR Marked Response  
ms millisecond  
mTOR  mammalian target  of rapamycin  
NIAID  National  Institute  of Allergy  and Infectious  Diseases  
NSAID  non-steroidal  anti-inflammatory drug 
PD pharmacodynamics  
PD Progressive  Disease  
PEG polyethylene glycol  
PLA poly [D,L -lactide]  
Plt platelet  
PPS Per Protocol Set 
PR Partial  Response  
PrGA  Provider  Global  Assessment  of Disease  Activity  
PT Preferred  Term  
PT prothrombin time 
QD once  daily  
RA rheumatoid  arthritis  
RBC  red blood  cell 
RCTC  Rheumatology  Common  Toxicity  Criteria  
PROPRIETARY AND  CONFIDENTIAL  PAGE  22 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Abbreviation  or Specialist  Term  Definition  or Explanation  
RDW  red cell distribution  width  
SAE serious  adverse  event  
SAP statistical  analysis  plan 
Scr Screening  Period  
SD Stable  Disease  
SEL-212H  high dose of  SEL-212 
SEL-212L  low dose of  SEL-212 
SF-36 Short  Form Health  Survey  
SOC  System  Organ  Class  
SS Safety Set 
SUA  serum  uric acid 
SVP Synthetic  Vaccine  Particle  
TEAE  treatment -emergent  adverse  event  
TID three times  daily  
UE Unable to Evaluate  
ULN  upper  limit of normal  
ULT  urate  lowering  therapy  
US ultrasound  
US FDA  United  States  Food  and Drug  Administration  
USP United  States  Pharmacopeia  
WBC  white  blood  cell 
PROPRIETARY AND  CONFIDENTIAL  PAGE  23 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
5. INTRODUCTION  
5.1 Gout  and Refractory Gout  
Gout is an intermittent inflammatory arthritis characterized by elevated uric acid levels and 
caused by the formation of urate crystals in joint fluid leading to intensely painful joint 
inflammation. Chronic hyperuricemia leads to further deposition of uric acid in soft tissues 
resulting in destructive arthritis and formation of tophi and renal calculi ( Choi 2005 , So 2008 , 
Wortmann 2008 ). Gout is a common disease with in creasing incidence, driven mainly by an 
aging  population,  with some  contribution  from  the increasing  prevalence  of obesity  and the use 
of diuretics ( Choi 2006 , Luk 2005 ). 
The incidence of gout increases as circulating uric acid levels increase ( Campion 1987 ) and 
lowering  circulating  urate  levels  is a primary  means  of managing  gout.  The American  College  of 
Rheumatology guidelines recommend lowering uric acid level to at least below 6 mg/dL and 
preferably below 5 mg/dL ( Khanna 2012a , Khanna 2012b ). 
The progression  of gout is believed  to have  4 pathophysiological  stages  (Dalbeth  2011 ): 
1. Hyperuricemia  without  monosodium  urate  crystal  deposition  or gout 
2. Crystal  deposition  without  symptomatic  gout 
3. Crystal  deposition  with acute  gout flares  
4. Advanced  or severe  gout,  characterized  by tophi,  chronic  gouty  arthritis,  and radiographic 
erosions  
 
Refractory gout is a serious condition affecting approximately 50,000 patients in  the United 
States  and is characterized  by uric acid levels  that are not adequately  controlled  by approved 
therapies.  
5.2 Symptoms  of Gout 
Symptoms and their development have a broad spectrum of severity. Most symptoms present as 
intermittent  attacks  or flares  while  others  present  as more  severe,  chronic  disease  affecting  one or 
more joints with tophi, sometimes referred to as chronic tophaceous gouty arthropathy  
(Khanna  2012a ). In chronic gout,  tophi  commonly  develop  in the fingers,  hands,  and feet around 
the ole cranon, and under the skin on the ears, but may also develop in other tissues and organs 
such as the kidneys and heart valves ( Ryan 2016 ). Pro -inflammatory cytokines and white cell 
debris are usually present in tophi, which suggest a state of chronic monosodium urate -crystal - 
stimulated inflammation ( Dalbeth 2011 ). These tophi can erupt through the skin, become 
inflame d and painful, and discharge urate crystals and eventually may cause deformities and 
secondary  osteoarthritis  (Ryan  2016 ). They  can infiltrate into  the bone,  causing  bone  erosion  and 
joint da mage ( Dalbeth 2011 ). Additional complications include obstruction of the joint and 
infection  as well as urolithiasis  with uric acid stones  or calcium  oxalate  stones  (Ryan  2016 ). The 
presence of tophi is associated with more frequent flares, which may be so painful and  
PROPRIETARY AND  CONFIDENTIAL  PAGE  24 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
debilitating  that they lead to joint replacement  or surgical  excision.  Over time,  flares  become 
polyarticular, additive, and increase in severity ( Brook 2010 ). 
5.3 Gout  and Hyperuricemia:  Exacerbation  of Existing  Comorbidities  
The effect of chronic, severe, refractory gout on quality of life is more pronounced in patients 
with medical  comorbidities  as these  complicate  the therapeutic  management  of their symptoms 
and increase their risk of cardiovascular events and all -cause mortality. It is also well - 
documen ted that the presence of these comorbidities has a significant impact on patientsâ€™ 
physical functioning, healthcare utilization, and quality of life ( Khanna 2012a ). 
Chronic, uncontrolled gout  and hyperuricemia are associated with metabolic disorders, type 2 
diabetes, hypertension, and renal and cardiovascular diseases ( Strand 2012 ; Becker 2009 ; 
Chandratre 2013 ). There is strong evidence that shows hyperuricemia contributes to worse 
outcomes under these conditions, and there is increasing mechanistic, e pidemiological, and 
clinical  data to indicate  that elevated  serum  uric acid (SUA)  levels  can exacerbate  and contribute 
to the progression of comorbidities ( Rock 2013 ; Mallamaci 2015 ). 
Data from 5707 patients in the National Health and Nutrition Examination Survey (NHANES) 
were  obtained  from  2007 -2008,  and prevalence  of major  gout comorbidities  were  correlated  with 
hyperuricemia levels ( Zhu 2012 ). This analysis revealed the presence of hypertension, chronic 
kidney disease, obesity, diabetes, nephrolithiasi s, myocardial infarction, heart failure, and stroke 
was substantially higher in individuals with gout compared to those without gout. Furthermore, 
the prevalence of these comorbidities increased proportionally to the level of hyperuricemia,  
with the incide nce of comorbidities being highest among individuals with both gout and 
hyperuricemia.  
5.4 Impact  on Quality  of Life 
One longitudinal study in  this patient population reports  that approximately 70% of  patients  with 
chronic refractory gout have at least 1 tophus and an average of 7 flares per year. In a separate 
study  of chronic  refractory  gout,  patients  self-reported  more  than 60% of these  flares  as crippling 
(Brook 2010 ). Symptoms of pain, limited mobility, and disability are debilitating and deeply 
affect physical function and emotional and social functioning, and disease severity correlates 
with a marked compromise in quality of life ( Strand 2012 , Becker 2009 ). 
The relationship between self -reported quality of life and disability and disease severity have 
been evaluated in multiple clinical studies. Over 100 subjects with chronic refractory gout 
evaluated using the Medical Outcomes Study Short Form -36 assessment, and results revealed 
that patients  with chronic  refractory  gout have significantly  lower  subscales  analogous  to those 
of 75 -year old individuals ( Becker 2009 ). Specifically, disease severity, as characterized by 
number of flares in the past year, number of tender or swollen joints, or presence of tophi, 
significantly  correlates  with worse  quality  of life scores  in all areas,  which  include  bodily  pain, 
general health, mental health, physical functioning and vitality. Subjects with comorbidities  
PROPRIETARY AND  CONFIDENTIAL  PAGE  25 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
experienced  worse  physical  functioning.  Notably,  their scores  did not improve  over the 52-week 
period despite undergoing maximal medical management ( Strand 2012 ). 
There is also evidence that gout affects workplace productivity, as studies in patients with 
chron ic, refractory  gout self-report  work  absences  due to flares,  losing  25.1 workdays  on average 
per year.  Another study specifically found employees with gout missed 4.56 more days of work 
per year than those without gout ( Edward s 2011 ). 
Hospitalizations  with a principal diagnosis  of gout has  steadily increased over the past 2 decades 
(Lim 2016 ). In contrast, hospitalizations due to rheumatoid arthritis (RA) has dramatically 
decreased over this same time period correlating with the development of effective biologic 
drugs to treat RA.  In 2005, the number of hosp italizations due to gout exceeded the number of 
hospitalizations  due to RA, and this gap has steadily  increased.  Hospitalization  costs  for gout and 
RA show a similar trend. Similarly, general population studies have shown a substantial 
reduction  in prematu re death  due in RA patients  but not in gout  patients  (Rai 2016 ). The findings 
likely reflect lack of effective therapies for severe gout.  
Together, these data show that the burden of chronic, severe, refractory gout extends well 
beyond that of physical discomfort, affecting almost every domain of life thus stressing the 
seriousness of the disease and an unmet need for new therapies given its refractory nature. 
Lowering serum urate levels can prevent further deposition of urate crystals, thus leading to a 
reduction in flare in cidence and resolution of existing tophi. The American College of 
Rheumatology  guidelines  recommend  a target  serum  urate  of less than 6 mg/dL  for patients  on 
urate lowering therapy, with a target of less than 5 mg/dL for patients with chronic, severe 
disea se, because this level is associated with more rapid resolution of tophi ( Dalbeth 2011 ). 
5.5 Approved  Therapies  for Chronic  Gout  Refractory  to Conventional  Therapy 
An estimated 160,000 gout patients fail to normalize their levels of SUA, have symptoms that 
are uncontrolled  with the currently  available  treatments  aimed  at lowering  urate  levels,  or suffer 
from comorbidities that preclude their use of conventional therapies ( Richette 2013 , Strand  
2012 ). Lack of treatment options leads to unabated disease progression.  
Currently, conventional therapies for the treatment of gout involve the inhibition of uric acid 
production and  the improvement of uric acid renal clearance.  The administration of  exogenous 
uricase, an enzyme not present in hum ans that converts uric acid into the water -soluble 
compound,  allantoin,  is used only in instances  of gout that is refractory  to first and second  lines 
of therapy ( Dalbeth 2011 ). 
There  are 2 uricase  products  currently  used to treat hyperuricemia:  rasburicase  (ELITEKÂ®) and 
pegloticase (KrystexxaÂ®). 
PROPRIETARY AND  CONFIDENTIAL  PAGE  26 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Rasburicase is a recombinant, unpegylated  urate -oxidase enzyme produced by genetically 
modified  S. cerevisiae . It is indicated  for tumor  lysis syndrome,  and its use in treating  gout is off- 
label. Its clinical use in gout is limited because it is highly immunogenic and has a short plasma 
half-life at approximately  18 to 24 hours,  making  it an unsuitable  treatment  for chronic  refractory 
gout ( Terkeltaub 2009 ). 
Pegloticase is a pegylated recombinant porcine - or baboon -derived uricase. It is currently the 
only FDA -approved  product  for the treatment  of chronic  gout refractory to  conventional  therapy 
(KRYSTEXXA Prescribing Information 2018 ). While its use is associated with  improvements in 
musculoskeletal  function,  quality  of life, and pain,  only approximately  42% of patients  maintain 
a target serum urate level less than 6 mg/dL after 6 months of the approved dose regimen of  
8 mg once every 2 weeks. The vast majority of patients (92%) develop anti -pegloticase 
antibodies. High titer antibodies appear to adversely affect the pharmacokinetics and 
pharmacodynam ics of the enzyme  and are associated  with a decrease  in therapeutic  response  and 
increased risk of infusion reactions. Approximately 26% of patients taking Krystexxa report 
infusion reactions, 6.5% experience anaphylaxis, and the incidence of infusion reac tions 
correlate with high anti -pegloticase antibody titer. These adverse events are typically preceded 
by a loss of urate -lowering effects.  
In addition to infusion reactions and gout flares, the most common adverse reactions with 
Krystexxa  are nausea,  contusion,  nasopharyngitis,  constipation,  chest  pain,  anaphylaxis,  and 
vomiting. In  the 2 pivotal  trials, there were 4 reported  cases  of exacerbations  of pre -existing 
congestive heart failure in subjects receiving Krystexxa every 2 weeks.  
The high rate of treatment  failure  and the potential  for anaphylactic  reactions  have  resulted  in 
limited use of Krystexxa since its approval.  
5.6 Unmet  Medical  Need  
Current, approved uricase products carry substantial safety risks associated with 
immunogenicity,  including  anaphylaxis,  as well as reduced  efficacy  over time as antibodies 
develop against the exogenous enzyme.  
Selecta  Biosciences  has developed SEL -212, the first drug product  designed  to reduce  or prevent 
an immunologic response and improve efficacy, safety, and  tolerability of a uricase enzyme 
(pegadricase) in patients who require long -term treatment to manage symptoms and  progression 
of chronic refractory gout. Selecta uses its proprietary, antigen -specific Synthetic Vaccine 
Particle (SVP) platform to encapsula te the approved immunomodulatory drug, rapamycin, to 
mitigate formation of anti -drug antibodies by inducing antigen -specific regulatory T cells.  
Selecta  is leveraging  its nanoparticle  technology  encapsulating rapamycin  (SVP -rapamycin)  with 
the goal of inducing durable antigen -specific immune tolerance to pegadricase, a pegylated 
uricase. Specifically, SEL -212, in its current formulation, is a combination intravenous drug 
product that consists of a pegylated recombinant uricase (pegadric ase; SEL -037) and a  
PROPRIETARY AND  CONFIDENTIAL  PAGE  27 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
biodegradable  nanoparticle  containing  rapamycin  (SEL -110.36),  a small  molecule  inhibitor  of 
the mammalian target of rapamycin (mTOR) pathway. Pegadricase is derived from Candida 
utilis and metabolizes poorly soluble uric acid to the more soluble metabolite, allantoin.  
Administration  of SEL-110.36  just prior  to pegadricase is  intended  to induce  immune  tolerance 
to prevent the formation of anti -uricase antibodies that may compromise efficacy or safety of 
pegadricase.  
The development  of SEL-212 remains  focused  on mitigating  the formation  of antidrug  antibodies 
with the goal of providing a product with better efficacy and safety profiles in patients than the 
only approved available therapy.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  28 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
6. STUDY  OBJECTIVES  AND  ENDPOINTS  
6.1 Study  Objectives  
6.1.1 Primary  Objective  
The primary  objective  of this study  is to assess  the reduction  in SUA  in patients  treated  with 
SEL-212 compared to KRYSTEXXA.  
6.1.2 Secondary  Objectives  
The secondary  objectives  of this study  are to  assess  improvement  of the following  parameters  in 
patients treated with SEL -212 compared to KRYSTEXXA:  
â€¢ Gout  flares  
â€¢ SUA  control  
â€¢ Joint  tenderness  and swelling  
â€¢ Quality  of Life (QoL)  
6.2 Study  Endpoints  
6.2.1 Primary  Endpoint  
The primary  endpoint  of this study  is the comparison in  the percentage  of patients  on SEL-212 
vs. KRYSTEXXA  who achieve and maintain reduction of SUA  < 6 mg/dL for  at least 80% of 
the time during Treatment Period 3 and Treatment Period 6  
6.2.2 Secondary  Endpoints  
The secondary  endpoints  of this  study  are: 
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve  and 
maintain reduction of SUA < 6 mg/dL for at least 80% of the time during Treatment 
Period 6  
â€¢ Comparison  in the percentage  of patients  on SEL-212 vs. KRYSTEXXA  who achieve  and 
maintain reduction of SUA < 6 mg/dL for 100% of the time during Treatment Period 6  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  in pre -dose SUA  values  
> 6 mg/dL during Treatment  Periods  2-6 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  in health 
questionnaires  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of gout flare incidence  per 3- 
month period (Treatment Periods 1 -3 and Treatment Periods 4 -6) 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of gout flare frequency  per 3- 
month period (Treatment Periods 1 -3 and Treatment Periods 4 -6) 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  from  Baseline 
to Treatment Period 6 in number of tender joints  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  from  Baseline 
to Treatment Period 6 in number of swollen joints  
PROPRIETARY AND  CONFIDENTIAL  PAGE  29 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
6.2.3 Safety  Endpoints  
The safety  endpoints  of this study are: 
â€¢ Safety  and tolerability  of SEL-212 compared  to KRYSTEXXA  as assessed  by AEs, 
serious AEs (SAEs), deaths, and discontinuations due to AEs  
â€¢ Additional safety assessments will include review and evaluation of laboratory testing 
including  hematology,  coagulation,  chemistry,  urinalysis;  vital signs;  12-lead ECGs;  and 
physical examination findings.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  30 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
7. INVESTIGATIONAL  PLAN  
7.1 Overall  Study  Design  
This study is a randomized, open -label, parallel -arm study  to compare the safety and  efficacy 
profiles of SEL -212 and KRYSTEXXA. Approximately 150 patients wi ll be randomized 1:1 
prior to Baseline to receive treatment with  SEL-212 or KRYSTEXXA for 6 months. Efficacy 
assessments,  as measured  by SUA  levels,  will be conducted  at intervals  that are appropriate  to 
determine treatment effect differences, including at month 3 and month 6. Assessments of 
qualitative  endpoints  will be conducted  on an assessor -blinded  basis.  Safety  will be monitored 
throughout the study.  
The study  will be divided  into 3 study  periods:  Screening,  Treatment,  and Follow -up, described 
below. The study is depicted schematically in Figure 1 . 
The total duration of participation in the study will range from approximately 26 to 31  weeks 
(184 to 219 days)  for patients  randomized  to SEL-212 and approximately 28  to 33 weeks  (198 to 
233 days) for patients randomized to KRYSTEXXA as follows:  
â€¢ Screening  and/or  washout  and premedication  period:  up to 45 days (up to 6.5 weeks)  
â€¢ Treatment:  168 days (24 weeks)  for SEL-212 KRYSTEXXA  
â€¢ Safety  Follow -Up: 30 (+ 4) days after the  date of last  infusion  
o SEL-212: Last scheduled  infusion  on Study  Day 140 
o KRYSTEXXA:  Last schedule  infusion  on Study  Day 154 
7.1.1 Screening  Period  
After  providing  written  informed  consent,  the patient  is considered  enrolled  in the study.  Patients 
will be evaluated for inclusion during the Screening Period. For all patients, the standard 
Screening Period will be up to 45 days prior to Baseline. Concurrently with the Screening 
Period, a premedication period with colchicine of at least 7 days prior to Baseline for potential 
gout flare will be required for all subjects, and a washout period of at least 7 days will be 
required prior to Baseline for p atients on any urate -lowering therapy (ULT).  
7.1.2 Treatment  Period  
The total duration  of treatment  will be 6 months.  Eligible  patients  will be randomized  1:1 prior  to 
Baseline to receive SEL -212 or KRYSTEXXA.  
Study  patients  in the SEL-212 arm will receive  study  drug every  28 days coinciding  with Day 0 
of each Treatment Period for a total of up to 6 infusions of SEL -212. 
Study  patients  in the KRYSTEXXA  arm will receive study  drug according  to the manufacturerâ€™s 
prescribing  information,  i.e., every  14 days coinciding  with Day  0 and Day 14 of each Treatment 
Period for a total of up to 12 infusions of KRYSTEXXA.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  31 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 
 
Prior to infusion, all patients will receive a standardized regimen of premedication to minimize 
the potential  for infusion  reactions  during  study  drug administration.  After  completing  the study 
drug infusions, patients will remain at the investigational site for at least 1 hour for safety 
assessments.  
Refer  to Section 10 for details  about  study  drug administration.  
 
With  each dose,  a blood  sample  will be drawn  for assessment  of SUA  level immediately  prior  to 
infusion (ie, Time 0h) with SEL -212 or KRYSTEXXA, 1 hour after the infusion of the second 
component of SEL -212 or of KRYSTEXXA is completed. SUA levels will be assessed through 
additional post -infusion blood samples at  pre-determined time points. Every effort  will be made 
to obtain blood samples at the same time of day of  each study visit.  
Gout  flares  will be assessed at  every  visit.  QoL and joint swelling  and tenderness  will be 
assessed on Day 0 of Treatment Period 1 and 4, and at the end of Treatment Period 6.  
Assessments  of qualitative  endpoints  (health  questionnaires  and joint assessment) will  be 
conducted on an assessor -blinded basis.  
On dosing  days,  safety  laboratory  samples  will be collected  pre-infusion  and per Schedule  of 
Events in both the SEL -212 arm and the KRYSTEXXA arm. Concomitant medications and 
procedures and adverse events (AEs) will be monitored continuously during the study.  
7.1.3 Follow -Up Period  
Patients will be followed for safety monitoring for 30 (+ 4) days after their final study drug 
infusion and will have an End of Study visit by telephone. Patients who terminate the study 
prematurely  will have all Early  Termination  assessments  performed.  Patients who  terminate  the 
study  prematurely  who are unable  to be on-site for the Early  Termination  visit will be contacted 
by telephone for safety follow -up. 
Figure  1: Study  Schematic  
 
 
 
7.2 Number  of Patients  
The study  will randomize  approximately  150 patients  with chronic  refractory  gout.  
 
7.3 Treatment  Assignment  
Patients  will be randomized  1:1 to receive  open -label  treatment  with SEL -212 or KRYSTEXXA.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  32 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
7.4 Dose  Adjustment  Criteria  
Unless  otherwise specified,  study  drug will be administered  as described  in Section  9 and 
Section 10. 
7.4.1 Safety  Criteria  for Adjustment  or Stopping  Doses  
7.4.1.1  SEL -212 
A patient  randomized  to treatment  with SEL-212 will be withdrawn  from  study  drug for meeting 
the following stopping rule:  
â€¢ In the SEL -212 arm: SUA  level  > 1.0 mg/dL measured  at the Day 21 visit of Treatment 
Period  1 or SUA  level  > 6.0  mg/dL  at the Day 21 visit of Treatment  Periods  2, 3, 4, or 5 
 
The window  for all Day 21 visits  is -2/+1 days.  
 
If a Day 21 visit SUA value drawn within the protocol window is not available, but if a SUA 
value  drawn  at an unscheduled  visit after the Day 21 window  is available  prior  to dosing  that is 
â‰¤ 1.0 mg/dL during  Treatment Period 1 or  â‰¤ 6.0 mg/dL during  Treatment Periods 2,  3, 4, or 5, 
the patient  will not be required  to be withdrawn from  study  drug and may be eligible  to receive 
their subsequent dose.  
If 1) a Day 21 visit SUA value drawn within the protocol window is not available and no 
subsequent SUA results are available or 2) a Day 21 visit SUA value drawn within the protocol 
window is not available and a subsequent SUA drawn at an unscheduled visit after the Day 21 
window  is > 1.0 mg/dL during  Treatment  Period  1 or > 6.0 mg/dL  during  Treatment  Periods  2, 3, 
4, or 5, then the patient will be withdrawn from study drug based on the protocol deviation.  
If withdrawn from study drug, the patient will continue study visits to the end of Treatment 
Period 6. At the discretion o f the Investigator, the patient will be permitted to return to urate 
lowering  therapy  60 days after the patientâ€™s  last study  drug treatment.  Urate  lowering  therapy 
shall not be SEL -212 or KRYSTEXXA.  
7.4.1.2  KRYSTEXXA  
A patient  randomized  to treatment  with KRYSTEXXA  and who has started  receiving  treatment 
with study drug will be withdrawn from study drug for meeting the following stopping rule:  
â€¢ In the KRYSTEXXA  arm: SUA  level  > 6.0 mg/dL  measured  on 2 consecutive  pre-dose 
measurements, based on the following  assessments:  
o If a pre-dose SUA  level  is > 6.0 mg/dL,  then the Investigator  will have  the option  to 
schedule a second SUA measurement to occur 2 days before the next scheduled 
KRYSTEXXA dosing day. The pre -dose SUA collected on Day 0 of Treatment 
Period 1 shall not be used in determining whether to invoke the stopping rule.  
o If the second  measured  SUA  level  is > 6.0 mg/dL,  then the Investigator  will withdraw 
the patient from study drug per the stopping rule.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  33 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
o If the second  measured  SUA  level  is â‰¤ 6.0 mg/dL,  the patient  can proceed  to dosing 
with KRYSTEXXA. However, SUA will be assessed on the day of dosing, per 
protocol, to be used determining consecutive pre -dose measurements for future 
stopping rules.  
 
If withdrawn from study drug, the patient will continue study visits to the end of Treatment 
Period 6. At the discretion of the Investigator, the patient will be permitted to return to urate 
lowering  therapy  60 days after the patientâ€™s  last study  drug treatme nt. Urate  lowering  therapy 
shall not be SEL -212 or KRYSTEXXA.  
7.4.2 Criteria  for Adjustment  or Stopping  Doses  
An independent Data and Safety Monitoring Committee (DSMC) will be formed by charter to 
assist  in reviewing  safety  data and may provide  recommendations  to the Sponsor  regarding  study 
drug dose adjustment or study termination.  
7.5 Criteria  for Study  Termination  
The study can be terminated  at any  time at the Sponsorâ€™s sole discretion. Otherwise,  the study 
will be terminated  when  all patients  have  completed  follow -up assessments  (Section  20) or the 
Sponsor or regulatory agency(ies) have determined there is an unacceptable risk to patients or 
additional dosing or procedures are not war ranted or necessary.  
The study  may be terminated  at a particular  investigational  site under  the following  conditions:  
â€¢ The Investigator  fails to enroll  patients  at an acceptable rate; 
â€¢ The Investigator  fails to comply  with pertinent  regulations;  
â€¢ There  is insufficient  adherence  (i.e., compliance)  to the protocol;  
â€¢ Knowingly  false information  is submitted  to the IRB,  Sponsor  or designee,  or regulatory 
authorities.  
7.6 Study  Rationale  
7.6.1 Rationale  for the Study  Design  
Study  SEL-212/202  is a randomized,  open -label,  parallel -arm study  to compare  the safety and 
efficacy profiles of SEL -212 to KRYSTEXXA.  
A randomized, controlled study is the gold -standard for evaluation of efficacy in clinical 
research.  Randomized,  controlled  studies  are quantitative,  compar ative,  controlled  experiments 
in which treatment effect sizes may be determined with less bias than observational trials.  
Randomization  is considered  the most  powerful  experimental  design  in clinical  trials:  with other 
variables  equal between groups, on average, any differences  in outcome can be attributed to the 
intervention.  
The study will be conducted on an open -label treatment basis; therefore, all patients, 
Investigators,  study  personnel,  and Sponsor  personnel  involved  in the conduct  of the study  will 
PROPRIETARY AND  CONFIDENTIAL  PAGE  34 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
have access to the randomized treatment assignments. Only the assessments of qualitative 
endpoints (health questionnaires and joint assessment) will be conducted on an assessor -blinded 
basis.  The open -label  design  was selected  because  of the substantial  differences  in administration 
of SEL -212 and KRYSTEXXA ( Section 10) and the practicality of maintaining the treatment 
blind. The parallel  arms  involving active treatment will permit  adequate statistical  comparison of 
the groups for efficacy and safety signal detection.  
KRYSTEXXA was sel ected as the active comparator because it is approved for this patient 
population  and because  the exogenous  protein  carries  similar  risks  to the SEL-037 component  of 
SEL-212. 
7.6.2 Rationale  for the Study  Population  
The selection of  this study population ( Section 8) is based primarily on the desired therapeutic 
indication  that the Sponsor  will seek.  Other  selection  criteria  were  set in order  to maximize  the 
ability to detect efficacy signals while minimizing any undue risk to the enrolled patients.  
Therefore, the severity and refractoriness of the patientâ€™s disease and SUA level are key 
Inclusion Criteria ( Section 8.1). In order to enhance the safety of patients on treatment, key 
Exclusion  Criteria  involve  history  of severe  allergies  or allergies  to products  that have similar 
features to the components of SEL -212, medical factors that might be exacerbated while on  
treatment, and prior exposure to experimental or marketed uricase therapies.  
7.6.3 Rationale  for the Selected  Dose  
Dose selection for  this study was based on safety and efficacy analyses of the clinical 
development program for SEL -212, beginning with a complete d Phase 1b study 
(Study  SEL-212/101:  â€œA Phase  I Single  Ascending  Dose  Safety,  Pharmacokinetic  and 
Pharmacodynamics Study of SEL -212 in Subjects with Elevated Blood Uric Acid,â€  
[STUDY_ID_REMOVED]  ) and a currently  ongoing  Phase  2 study  (Study  SEL-212/201:  â€œAn Open  Label 
Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL -212 
Followed by Open Label Administration of SEL -037 in Subjects with Symptomatic Gout and 
Elevated Blood Uric Acid ,â€ [STUDY_ID_REMOVED]).  
Doses  of KRYST EXXA  selected  for this study  are based  on the manufacturerâ€™s  approved 
labeling ( KRYSTEXXA Prescribing Information 2018 ). 
7.6.3.1  Phase  1b Study  with SEL -212 
This was a Phase  1b double -blind,  sequential,  single -ascending -dose study  (SEL -110; Cohorts  1, 
3, 5, and 7) combined with an open label, single -ascending -dose study (SEL -212; Cohorts 2, 4, 
6, 10, 12 and 14) to assess the safety, tolerability, and PK of SEL -212 and SEL -110. 
Additionally, the study was to assess the PD (ability to reduce  SUA) and immunogenicity 
(ability  to prevent  ADAs  to uricase  and pegadricase)  of SEL -212. Generally,  patients  were  dosed 
on a cohort basis in an ascending stepwise manner. A control group was dosed with SEL -037 
only.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  35 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
In the Phase 1b study, patients (N = 64) with a serum uric acid  level â‰¥  6 mg/dL, with or without  
a history of gout, were administered SVP -rapamycin alone, pegadricase alone, or SEL -212 as an 
intravenous infusion. Mitigation of ADAs and a dose -dependent reduction in SUA levels 
occurred  from  study  Day 1 to Day 30 in patients  administered SEL -212 (data  on file).  There  was 
no effect of SVP -rapamycin alone on SUA levels, and patients administered pegadricase alone 
developed ADAs that resulted in loss of SUA control by Day 14. SEL -212 was generally well 
tolerated at all dose levels. The maximum tolerated dos e of SVP -rapamycin was determined to  
be 0.3 mg/kg. Data from this study were used to select additional dose levels of each  component 
of SEL -212 for evaluation in the currently ongoing Phase 2 study SEL -212/201.  
7.6.3.2  Phase  2 Study  with SEL -212 
The Phase 2 study SEL-212/201 was designed as an open -label, multiple -dose clinical study of 
the combination drug, SEL -212, which was combined with an open -label, multiple -dose 
evaluation of pegadricase alone (SEL -037). Part A of the study consisted of three 28 -day 
treatmen t cycles  of SEL -212, which  was then followed  by Part B, which consisted  of two 28-day 
treatment cycles of SEL -037 alone, with  a primary objective of assessing the safety,  tolerability, 
PK, PD of SEL -212 (i.e., the combination of SEL -110 and SEL-037). Part C of the study 
consisted of five 28 -day treatment cycles of SEL -212 with a primary objective of assessing the 
safety, tolerability, PK, and PD of SEL -212. Additional assessments include the ability of  
SEL-212 to reduce  serum  uric acid levels  and prevent  anti-drug antibodies  to uricase,  PEG,  and 
pegadricase.  
Overall, in the currently ongoing Phase 2 study with SEL -212, SUA levels have remained 
consistently below 6 mg/dL in 70% to 89% of evaluable Part A patients administered SEL -212 
once  month ly for 3 months.  Similarly,  in Part C where  SEL-212 was administered  once monthly 
for 5 months, SUA levels have remained below 6 mg/dL in 61% to 75% of evaluable patients 
through the end of  the fifth treatment period.  All evaluable Part C patients  who had SUA  levels 
below 6 mg/dL at week 12 also had SUA below 6 mg/dL at Week 24. The control of SUA has 
occurred in the context of low incidences of infusion reactions, anaphylaxis, and gout flares as 
well as treatment -emergent adverse events (TEAEs) known t o be potentially associated with 
sirolimus (RapamuneÂ®). Data support a once monthly dosing regimen.  
7.6.4 Rationale  for the Primary  Efficacy  Endpoint  
The incidence of gout increases as circulating uric acid levels increase ( Campion 1987 ) and 
lowering  circulating  urate  levels  is a primary  means  of managing  gout.  The American  College  of 
Rheumatology recommends lowering urate levels to a target of less than 6 mg/dL at minimum 
(Khanna 2012a ) to improve the signs and symptoms of gout.  
Based on a proposed indication of treatment of chronic gout refractory to conventional therapy, 
the objectives  of this study  design  are to assess  the reduction  in SUA  in cohorts  of adult  subjects 
treated with SEL -212 compared to KRYSTEXXA. The proposed primary endpoint is  
PROPRIETARY AND  CONFIDENTIAL  PAGE  36 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
comparison in the percentage of patients on SEL -212 vs. KRYSTEXXA who achieve and 
maintain  reduction  of SUA <  6 mg/dL  for at least 80% of the time during  Treatment  Period 3  and 
Treatment Period 6.  
7.6.5 Rationale  for Secondary  Efficacy  Endpoints  
Secondary  endpoints  were  selected  based  on symptoms  of chronic  gout as well as quality  of life 
as a consequence of chronic gout. Patients  with severe, chronic gout are often refractory to oral 
therapies and often present with swollen or tender joints. Exacerbation of gout (flare) and joint 
tenderness and swelling impact a patientsâ€™ ability to maintain physical activity and functioni ng 
and correspond to quality of life. Several instruments will be used to assess quality of life and 
will include patient -reported outcomes, provider -reported assessments, and generalized 
assessments of overall quality of life.  
7.7 Benefits  and Risks  
Chronic gout refractory to conventional therapy is a rare and serious condition associated with 
increased mortality rate and significantly decreased quality of life and for which there are very 
limited  treatment  options.  Data  from  the Phase  2 study SEL -212/201 provide  preliminary  clinical 
evidence demonstrating that SEL -212 is a substantial improvement over available therapy:  
â€¢ Substantially  increased  percentage  of patients  that maintain  control  of SUA  while  on 
therapy  
â€¢ Substantially  reduced  gout flare rate during  therapy  
â€¢ Substantially  reduced  risk of infusion  reactions  
â€¢ More  convenient  to and greater  compliance  by patients  because  of once  monthly  therapy  
â€¢ Acceptable  safety  at the doses  to be studied  in this Phase  2 study  
SEL-212 has the potential  to be an unprecedented  safe and effective  treatment  option  for patients 
for which  other  treatment  options  are inadequate. The overall  balance between  benefits  and risks 
appears  acceptable for the SEL -202/202 study of SEL -212 in the  intended population of patients 
with chronic gout refractory to conventional therapy.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  37 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
8. SELECTION  AND  WITHDRAWAL  OF PATIENTS  
8.1 Patient  Inclusion  Criteria  
A patient  must  meet  all of the following  criteria  to be eligible  for this study:  
 
1. Has provided  written  informed  consent  prior  to the conduct  of any study  specific 
procedures;  
2. Understands  and is willing  and able to comply  with study  requirements,  including  the 
schedule of follow -up visits;  
3. Has a history  of symptomatic  gout defined  as: 
a. â‰¥ 3 gout flares  within 18  months  of Screening or 
b. Presence  of â‰¥ 1 tophus  or 
c. Current diagnosis  of gouty  arthritis  
4. At the Screening  Visit:  male  age 21 â€“ 80 years,  inclusive,  or female  of non-childbearing 
potential age 21 -80 years, inclusive, where non -childbearing potential is defined as:  
a. > 6 weeks  after hysterectomy  with or without  surgical  bilateral salpingo - 
oophorectomy or  
b. Post-menopausal  (> 24 months  of natural  amenorrhea  or in the absence  of 
> 24 months  of amenorrhea,  1 documented  confirmatory  FSH measurement)  
5. Has at Screening  SUA  â‰¥ 7 mg/dL,  with chronic  refractory  gout defined  as having  failed 
to normalize SUA and whose signs and symptoms are inadequately controlled with 
xanthine oxidase inhibitors at the medically appropriate dose, or these drugs are 
contraindicated for the subject;  
6. Is negative  for anti-PEG  antibodies  at Screening;  
7. Has not participated  in a clinical  trial within  30 days of the Screening  Visit  and agrees  not 
to participate in a clinical trial for the duration of the study;  
8. Negative  serology  for HIV-1/-2 and negative  antigen  to hepatitis  B and negative 
antibodies to hepatitis C;  
9. Has adequate venous  access  and able to receive IV  therapy;  
10. If applicable,  has sufficiently  recovered  from  any prior  surgery to  allow  for successful 
completion of study procedures.  
8.2 Patient  Exclusion  Criteria  
A patient who  meets  any of the following  criteria will  be excluded  from  this study:  
 
1. Prior  exposure  to any experimental or  marketed  uricase  (e.g.,  pegloticase  [KrystexxaÂ®], 
pegadricase [SEL -037], rasburicase [Elitek, Fasturtec]);  
2. History  of anaphylaxis  or severe  allergic reactions  to medications;  
3. History of any allergy to pegylated products, including, but not limited to, peginterferon 
alfa-2a (PegasysÂ®), peginterferon alfa -2b (PegIntronÂ®), pegfilgrastim (NeulastaÂ®), 
pegaptanib  (MacugenÂ®), pegaspargase  (OncasparÂ®), pegademase  (AdagenÂ®), peg-epoetin  
PROPRIETARY AND  CONFIDENTIAL  PAGE  38 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
beta (MirceraÂ®), pegvisomant  (SomavertÂ®) certolizumab  pegol  (CimziaÂ®), naloxegol 
(MovantikÂ®), peginesatide (OmontysÂ®), and doxorubicin liposome (DoxilÂ®); 
4. Known  moderate and  severe  CYP3A4  inhibitors  or inducers  must  be discontinued  
14 days before  dosing  and patients  must remain  off the medication  for the duration  of the 
study, including natural products such as St. Johnâ€™s Wort or grapefruit juice;  
5. Drugs  known to interact with RapamuneÂ® such as  cyclosporine, diltiazem,  erythromycin, 
ketoconazole (and other antifungals) , nicardipine (and other calcium channel blockers), 
rifampin,  verapamil  unless  they are stopped  2 weeks  prior  to starting  the trial and will not 
be used during the trial;  
6. Initiation  or change  in dose of hormone -replacement  therapy  for menopausal  women  less 
than 1 month prior to the Screening Visit or during the Screening Phase would be 
exclusionary.  If after being on a stable dose of hormone -replacement therapy for  
1 month  the patient  may be considered  for the study  if she continues  to meet  all other 
inclusion and exclusion criteria;  
7. A gout flare during Screening that was resolved for less than 1 week prior to first 
treatment  with study  drug (exclusive  of synovitis/arthritis),  unless  the patient  has a 
history of inter -flare intervals < 1 week;  
8. Uncontrolled  diabetes  at Screening  with HbA1c  â‰¥ 8%; 
9. Fasting  Screening  glucose >  240 mg/dL;  
10. Fasting  Screening  triglyceride >  300 mg/dL;  
11. Fasting  Screening  low-density  lipoprotein  (LDL)  > 200 mg/dL;  
12. Glucose -6-phosphate  dehydrogenase  (G6PD)  deficiency;  
13. Uncontrolled  hypertension  defined  as blood  pressure  >170/100  mmHg  at both  Screening 
and 1 week prior to dosing;  
14. Individual  laboratory  values  which  are exclusionary  
o White  blood  cell count  (WBC)  < 3.0 x109/L 
o Serum  aspartate  aminotransferase  (AST)  or alanine  aminotransferase 
(ALT) > 3x upper limit of normal (ULN)  
o Estimated  glomerular  filtration  rate (GFR)  < 30 mL/min/1.73  m2 
o Hemoglobin  (Hgb)  < 9 g/dL 
o Serum phosphate < 2.0  mg/dL  
15. Patients  whose arrhythmia  is unstable on  current treatment;  
16. History  of coronary  artery  disease,  including  myocardial  infarction  or unstable  angina, 
within the last 6 months;  
17. Congestive  heart  failure,  New  York  Heart  Association  Class  III or IV; 
18. Unless  clinically  stable  and/or  appropriately  treated,  electrocardiogram  (ECG)  with 
evidence of prior myocardial infarction, clinically significant arrhythmia, or other 
abnormalities  that, in the opinion of the investigator,  are consistent with significant 
underlying cardiac disease;  
PROPRIETARY AND  CONFIDENTIAL  PAGE  39 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
19. History  of significant  hematological  disorders  or autoimmune  disorders,  and/or  subject  is 
immunosuppressed or immunocompromised;  
20. Subject  is currently  taking  dabigatran  (PradaxaÂ®),  rivaroxaban  (XareltoÂ®), 
edoxaban (SavaysaÂ®), warfari n (CoumadinÂ®), or apixaban (EliquisÂ®);  
21. Subject  has received  an inactivated  vaccine  in the previous  3 months  with respect  to the 
randomization date or has received a live virus vaccine in the previous 6 months with 
respect to the randomization date. Recombinant vaccines are excluded from this 
exclusion criterium;  
22. Subject  is planning  to receive  any live or  attenuated virus  vaccination  during  the study.  
23. History  of malignancy  within  the last 5 years  other  than basal  skin cancer;  
24. Any condition,  that in the opinion  of the investigator,  would  be negatively  affected  by 
rapamycin;  
25. Subjects  with a documented  history  of moderate  or severe  alcohol  or substance use 
disorder within the 12 months prior to randomization;  
26. Subjects  who,  in the opinion  of the investigator,  present  with a condition  that would 
compromise their safety or that would make study completion unlikely.  
8.2.1 Patient  Completion  and Withdrawal  Criteria  
8.2.1.1  Screen Failures  
A patient is considered enrolled in the study at the time of ICF signature. Any patient that is 
screened but not dosed will be considered a screen failure and the reason for failure will be 
documented.  Within  the 45-day screening  window,  out-of-range  laboratory  tests may be repeated 
up to 2 times before declaring a scre en failure. After the 45 -day screening window, patients can 
be re -screened once.  
8.2.1.2  Patient  Completion  
A patient will be considered to have completed  the study when the patient has completed Safety 
Follow -up that occurs 30 (+ 4) days after the final dose of s tudy drug. Enrolled patients who 
prematurely  discontinue  for any reason  before  completion  of the study  will be treated as  outlined 
below in Section 8.2.1.3.1 . 
8.2.1.3  Enrolled  Patient  Withdrawal  and Discontinuations  
8.2.1.3.1  Withdrawal  Procedures  
Early termination from the study occurs when an enrolled patient withdraws consent or the 
Investigator  terminates  a patient.  The reason  for withdrawal  will be evaluated  and recorded  in the 
case report f orm (CRF) and source documents. Patients that withdraw will not be replaced.  
Patients  may withdraw  consent  at any time. Reason(s)  for withdrawal  of consent,  failure  to return 
for the necessary visits, or termination from the study should be documented. All patients that 
withdraw early from the study, upon termination should have the Early Termination visit  
PROPRIETARY AND  CONFIDENTIAL  PAGE  40 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
assessments  completed  (i.e., End of Study  assessments)  (Section  20), if the assessments  pose no 
risk to the patient and the patient allows such assessments.  
The Investigator should consult with the Sponsor/medical monitor prior to withdrawing any 
patient from the study. Since  this is a multiple -dose study, once dosed, patients generally should 
not be terminated by the Investigator and should be followed through the end of Treatment 
Period 6, unless the patient withdraws consent or is lost to follow -up. In situations where 
continued  participation  in certain  aspects  of the study  pose a risk to the patient,  with consultation 
with the medical monitor, the Investigator should discontinue those procedures that pose a risk 
and should continue to collect data and conduct those assessments that do not put the patient at 
risk through the end of Treatment Period 6. Patients with compliance issues or major deviations 
that effect data quality will also continue to be followed through the end of Treatment Period 6 
collecting as much d ata on the patient as possible, unless otherwise indicated by the Sponsor.  
8.2.1.3.2  Patients  Lost To Follow -Up 
For patients to be considered as lost to follow -up, at least 3 contact attempts must be 
documented,  of which  the last must  be a letter  sent by a service  that requires  a delivery  signature 
record (e.g., US Postal Service certified letter or Federal Express/UPS letter that requires 
signature of delivery). If the letter is undeliverable or no response is received within  7 days, the 
patient will be considered t erminated due to lost to follow -up. 
PROPRIETARY AND  CONFIDENTIAL  PAGE  41 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
9. TREATMENT  OF PATIENTS  
9.1 Description  of Study  Drug  
SEL-212 is comprised of 2 components: SEL -037 and SEL -110.36 ( Table 1 ). Lyophilized 
SEL-037 supplied  as 40 mg SEL-037, with phosphate  buffer  and mannitol  as excipients,  in a 
20 mL borosilicate glass vial with a chlorobutyl rubber stopper and an aluminum -plastic 
combination  blue cap. SEL-110.36,  a lyophilized  powder  containing  synthetic  biodegradable 
polymeric nanoparticles encapsulating rapamycin, with sucrose and Tris buffer  
(tris(hydroxymethyl)aminoethane)  as excipients  in a 20 mL, Type  1 borosilicate  glass  vial with a 
chlorobutyl rubber stopper and an aluminum -plastic combin ation white cap. Vials are filled to 
provide 10 mg of SEL -110.36.  
Table  1: Investigational  Product  
 Investigational  Product  Investigational  Product  
Product Name:  SEL-037 SEL-110.36  
Dosage  Form:  Lyophilized  powder  for 
solution  Lyophilized  powder  for 
suspension  
Unit  Strength:  40 mg SEL -037 per  vial 10 mg SEL -110.36 per  vial 
Route  of Administration:  Intravenous  infusion  Intravenous  infusion  via syringe 
pump  
Physical  Description:  20 mL borosilicate  glass  vial 
with rubber stopper and 
aluminum -plastic blue 
combination cap  20 mL borosilicate  glass  vial 
with rubber stopper and 
aluminum -plastic white 
combination cap  
Manufacturer:  Manufactured  for Selecta 
Biosciences by 3S and  
Emergent  BioSolutions  Manufactured for Selecta 
Biosciences  by LSNE  Contract  
Manufacturing  
 
9.2 Concomitant  Medications  and Therapies  
Concomitant medications are permitted during this study unless otherwise restricted. 
Concomitant  medications  used in the 3 months  prior  to screening  and during  the study  will be 
documented.  
9.2.1 Uric Acid  Lowering  Therapy  
Uric acid lowering  therapy  (ULT)  including,  but not limited  to allopurinol,  febuxostat  (UloricÂ®), 
probenecid, lesinurad (ZurampicÂ®, DuzalloÂ®), and benzbromarone ULT, are not permitted for 
use during the study. Patients will undergo a ULT washout period prior to dosing with study 
drug according to the schedules described in Section 20. 
Patients  cannot  have  any prior  exposure  to or be presently  be taking  any experimental  or 
marketed uricase therapy, as defined in Exclusion Criterion 1 (Section 8.2). 
PROPRIETARY AND  CONFIDENTIAL  PAGE  42 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
9.2.2 Anticoagulants  Use 
Anticoagulant  use, as defined  in Exclusion  Criterion  20 (Section  8.2) is prohibited  during  the 
study.  
9.2.3 Hormone  Replacement  Therapy  
Hormone  replacement  therapy  in menopausal  women  should  remain  stable  throughout  the study.  
 
9.2.4 CYP3A4  Inducers  and Inhibitors  
The use of CYP3A4 moderate and severe inducers or inhibitors are prohibited 14 days prior to 
dosing  and during  the trial. Examples  of moderate  or severe  inducers  include,  but are not limited 
to carbamazepine -TegretolÂ®, phenobarbital, phenytoin -DilantinÂ®, rifampin/rifampicin -RifadisÂ®, 
rifabutin -MycobutinÂ®, St. Johnâ€™s Wort -Hypericum perforatum. Examples of moderate or severe 
inhibitors include, but are not limited to nefazodone -SerazoneÂ®, itraconazole -SporanoxÂ®, 
ketoconazole -NizoralÂ®, voricinazole -VfendÂ®, atraznavir -ReyatazÂ®, indinavir -CrixvanÂ®, 
nelfinavir -ViraceptÂ®, ritonavir -Norvir, saquinavir -InviraseÂ®, clarithromycin -BiaxinÂ®, 
telithomycin -KetekÂ®, and grapefruit juice.  
9.2.5 Other  Concomitant  Medications  
Patients  on medications  (e.g.,  antifungals  and/or  calcium  channel  blockers)  that do not rely  on a 
mechanism of action that  is known to increase the  level or effect of sirolimus (RapamuneÂ®) are 
permitted to continue taking thes e medications prior to and during the study, and will not be 
noted as a protocol deviation.  
9.3 Treatment  Compliance  
Study drug will be administered in the controlled environment of a clinical research center. 
Direct  observation  of the administration  of the study drug by study  staff will ensure  compliance. 
The date and time of the start and stop of drug administration and volume infused will be 
recorded.  
9.4 Randomization  and Blinding  
This is a randomized, open -label treatment study. Patients will be randomized 1:1 to receive 
SEL-212 or KRYSTEXXA.  Randomization  preferably  should  occur  7 days prior  to the first dose 
of study drug (ie, Day -7). The randomization will be stratified for tophus presence (yes/no).  
Assessments  of qualitative endpoints  will be conducted  on an assessor -blinded basis.  
Prior to study drug administration in Treatment Periods 2 through 6, the Investigator will 
determine  a patientâ€™s  eligibility  for treatment  with study  drug by evaluating  the patientâ€™s SUA 
level measured from the blood sample obtained from Day 21 of the most recently completed 
Treatment Period (SEL -212 cohort) or from the previous 2 measurements (KRYSTEXXA 
cohort).  
Study  personnel  will endeavor  to safeguard  the integrity  of the qualitative  endpoint  blind  to 
minimiz e bias in the study.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  43 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
10. STUDY  DRUG  MATERIALS  AND  MANAGEMENT  
10.1 Study  Drug  
This is a randomized, open -label  treatment study.  The designated  site representative  will prepare 
study drug on the day of treatment. Prior to study drug administration in T reatment Periods 2 
through 6, the Investigator will determine a patientâ€™s eligibility for  treatment with study drug by 
evaluating  the patientâ€™s  SUA  level  measured  from  the blood  sample  obtained  from Day  21 of the 
most recently completed Treatment Period (SEL -212 cohort) or from the previous 2 
measurements (KRYSTEXXA cohort).  
10.1.1  SEL -212 
SEL-212 is comprised  of 2 components: SEL -037 and SEL-110.36.  Refer  to Section  9.1 for 
complete descrip tions of the components.  
The dose level  to be investigated  in this study  will be: 
 
â€¢ SEL-212: consisting  of 0.15  mg/kg  SEL-110.36  and 0.2  mg/kg  SEL-037 
10.1.2  KRYSTEXXA  
KRYSTEXXA  (pegloticase  injection)  will consist  of commercially  available  study  drug. 
The dose level to be investigated in this study will be:  
â€¢ KRYSTEXXA:  8 mg (uricase  protein)  (KRYSTEXXA  Prescribing  Information  2018 ) 
10.2 Study  Drug  Packaging  and Labeling  
SEL-212 will be supplied  in vials  in individual  cartons  with cartons  and vials  unassigned  to a 
patient. KRYSTEXXA will be packaged according to the manufacturerâ€™s specifications.  
10.3 Study  Drug  Storage  
Upon  receipt  of the SEL -037 vials  at the clinical  site, the vials should  be stored  in a secured  way 
at 2Â°C to 8Â°C within the primary or secondary box container in order to protect the SEL -037 
from long -term light exposure.  
Upon  receipt  of the SEL-110.36  vials  at the clinical  site, the vials  should  be stored  in a secured 
way at 2Â°C to 8Â°C within the primary or secondary box container in order to protect the  
SEL-110.36  from long -term light exposure.  
 
KRYSTEXXA  will be handled  and stored  according  to the manufacturerâ€™s  currently  approved 
labeling ( KRYSTEXXA Prescribing Information 2018 ). 
10.4 Study  Drug  Preparation  
Doses  of SEL-212 are calculated  on a mg/kg  basis  according  to a patientâ€™s  weight.  For Treatment 
Period 1, the patientâ€™s Screening weight will be used for dose preparation. For the remaining  
PROPRIETARY AND  CONFIDENTIAL  PAGE  44 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Treatment Periods,  the patientâ€™s  weight  at the Day 21 visit from  the preceding Treatment  Period 
will be used for dose calculation. Detailed procedures and examples of dose calculations and 
study drug preparation are provided in the Study Operations Manual.  
10.4.1  SEL -037 Preparation  
Each vial of SEL -037 will be reconstituted with 6.9 mL of sterile water for inj ection, USP 
(United States Pharmacopeia or equivalent) which forms a 6 mg/mL concentrated solution and 
then the appropriate  dose diluted  for administration  in 100 mL of room  temperature  0.9%  sodium 
chloride for injection, USP. The full resultant  volume of the SEL -037-normal saline solution  
(100 mL saline + required volume of reconstituted SEL -037 + saline bag  manufacturing overfill) 
will be administered in the allotted time. Reconstituted SEL -037 is stable at room temperature  
for 18 hours and the  diluted SEL -037-normal saline solution for infusing should be used (i.e., 
infusion completed) within 6 hours of dilution. If not administered immediately, store 
refrigerated. The SEL -037 dose administration must be completed within 12 hours  of the start o f 
reconstitution.  
10.4.2  SEL -110.36  Preparation  
Each vial of SEL -110.36 will be reconstituted with 4.9 mL of sterile water for injection, USP 
(United States Pharmacopeia or equivalent) which forms a 2 mg/mL suspension before being 
drawn  into appropriate  size syringe/syringes  for IV infusion  with syringe  pump. Reconstituted 
SEL-110.36  is stable  for 24 hours  at room  temperature  at normal  light conditions.  SEL-110.36 
should be administered on the same day and as soon as possible after reconstitution. If not 
administe red immediately, store refrigerated. The SEL -110.36 dose must be completely 
administered within 12 hours of the start of reconstitution.  
10.4.3  KRYSTEXXA  Preparation  
Doses  of KRYSTEXXA  will be calculated  and prepared  based  on the manufacturerâ€™s  currently 
approved labeling ( KRYSTEXXA Prescribing Information 2018 ). 
Under appropriate aseptic technique, 1 mL of KRYSTEXXA will be withdrawn from the vial 
and injected into a single 250 mL bag of 0.9% Sodium Chloride Injection, USP or 0.45% 
Sodium  Chloride  Injection  USP for IV infusion.  The solution  will not be mixed  or diluted  with 
other drugs. Thorough mixing will be by inversion, not shaking. The diluted solution may be 
kept for 4 hours  at 2Â°C t o 8Â°C (36Â°F  to 46Â°F) and at room temperature (20Â°C to 25Â°C, 68Â°F  to 
77Â°F). It is recommended that diluted solutions be stored under refrigeration, not frozen, 
protected from light, and used within 4 hours of dilution.  
Detailed  procedures  for study  drug preparation  are provided  in the Study  Operations  Manual.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  45 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
10.5 Premedication  
10.5.1  Gout  Flares  (Prevention  and Treatment)  
All patients  that meet  all inclusion  and exclusion  criteria  will be premedicated  for gout flare 
prevention.  The regimen  will begin  at least 7  days prior  to the first dosing  of study  drug and 
continue for as long as the patient is participating in the clinical study.  
Patients not already taking colchicine will receive colchicine 1.2 mg as a single loading dose 
followed by 0.6 mg QD for  the remainder of participation in the trial. If the patient cannot 
tolerate  the loading  dose level  of 1.2 mg, then the patient  will initiate  and maintain  colchicine  at 
0.6 mg. Patients with a documented medical reason that describes a contraindication to 
colchicine will receive ibuprofen 600 mg TID or an equivalent NSAID unless the patient has a 
contraindication  to NSAID. At  the discretion  of the Investigator,  a proton  pump  inhibitor  may be 
prescribed with the NSAID as gastric prophylaxis. Patients with documented medical reasons 
that describe  contraindications  to both colchicine and NSAIDs  will receive no premedication for 
gout flare.  
Patients who began receiving a NSAID as gout flare prevention medication due to a 
contraindication  to colchicine  should continue  to receive  the NSAID  during  study  participation. 
These medications will be supplied by the clinic.  
As gout flares  are expected to occur despite preventative premedication, incidents  of gout flare 
are to be recorded  as an AE and treated  at the discretion  of the Investigator  to provide  adequate 
patient care.  
10.5.2  Premedication  with  Antihistamines  and Steroids  
All patients  in the study  will be pre-medicated  with oral antihistamines  and steroids  as follows 
for prevention of infusion reactions:  
â€¢ Prednisone  (40 mg) orally  approximately  24 (Â± 12) hours  prior  to dosing  (morning  before 
study drug dosing on Day 0)  
â€¢ Fexofenadine  (180 mg) orally  approximately  12 (Â± 2) hours  prior  to dosing  (evening 
before study drug dosing on Day 0)  
â€¢ Fexofenadine  (180 mg) orally  approximately  2 (Â± 1) hours  prior  to dosing  (day of study 
drug dosing)  
â€¢ Methylprednisolone (40  mg) (or equivalent)  IV approximately  1 (Â± 0.5) hours  prior  to 
dosing (day of study drug dosing)  
 
Refer  to Section  12.2.1.5  for guidance  on reducing  the risk of infusion  reactions  and for 
managing infusion reactions.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  46 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
10.6 Administration  
10.6.1  SEL -212 
Before  administration  of SEL-212, patients  will be premedicated  with antihistamines and 
steroids as described in Section 10.5. 
Patients  will receive  treatment  with SEL -212 on Day 0 of each Treatment Period  for a total of 
6 doses of study drug.  
All study  drugs  should  be administered  through  the same  IV access.  All blood  samples  should  be 
drawn f rom an alternative venous access.  
If an infusion reaction occurs, Investigators are permitted to use concomitant medications or 
treatments deemed necessary to provide adequate patient care. Investigators should also utilize 
the infusion reaction lab kit pr ovided in  the Study Operations Manual to collect  additional blood 
specimens. In the case of a Grade 3 or 4 infusion reactions occurring during an infusion, the 
administration  of study  drug should  be immediately  discontinued,  and the affected patient  should 
be treated according to the clinical trial siteâ€™s protocol for infusion reactions (e.g., monitoring, 
administration of antihistamines, corticosteroids, fluids and epinephrine, as clinically indicated).  
The reconstituted SEL -110.36 will be withdrawn from the vial  and dosed via IV infusion with a 
syringe infusion pump utilizing an appropriately sized syringe. SEL -110.36 will be infused at a 
rate of 3.0 mL/hr for the first 30 minutes, then a rate adequate to deliver the remaining dose 
volume over a peri od of 60 minutes concurrently with 125 mL normal saline. Following the 
infusion of SEL -110.36, the  main IV  line must be flushed with normal saline prior to the start of 
the SEL-037 infusion.  Refer  to the Study  Operations  Manual  for instructions  regarding  infusions 
for patients with medical history involving cardiovascular comorbidities.  
SEL-037 infusion will start within 15 minutes after completion of the SEL -110.36 infusion. 
SEL-037 will be infused  via infusion  pump  over a time period  of no less than 120 minutes.  If an 
infusion reaction occurs during the administration of SEL -037, the infusion may be slowed, or  
stopped  and restarted  at a slower  rate at the discretion  of the physician. Following  the infusion  of 
SEL-037, the main IV line must be flushed with normal saline.  
The Investigator is permitted  to modify  the infusion parameters (decrease the rate of  infusion or 
interrupt  the infusion)  ONLY  if medically  warranted  in response  to an AE. The Investigator  will 
notify the unblinded medical monitor of any changes in infusion parameters. Detailed 
instructions  for modifying the infusion parameters  are included in the Study Operations  Manual.  
10.6.2  KRYSTEXXA  
Before  administration  of KRYSTEXXA,  patients  will be premedicated  with antihistamines  and 
steroids as described in Section 10.5. 
PROPRIETARY AND  CONFIDENTIAL  PAGE  47 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Patients  will receive  treatment  with KRYSTEXXA  on Day 0 and Day 14 of each Treatment 
Period for a total of 12 doses of study drug.  
All study  drugs  should  be administered  through  the same  IV access.  All blood  samples  should  be 
drawn from an alternative venous access.  
KRYSTEXXA will administered based on the manufacturerâ€™s currently approved labeling 
(KRYSTEXXA  Prescribing  Information  2018 ). Detailed  instructions  for study  drug administration 
are provided in the Study Operations Manual.  
Before administration, the diluted solution of KRYSTEXXA should be allowed to reach room 
temperature, but never exposed to artificial heating (eg, hot water, microwave). The diluted 
solution  of KRYSTEXXA  should  be administered  by IV infusion  via gravity  feed,  syringe -type 
pump, or infusion pump over no less than 120 minutes. Following the infusion of 
KRYSTEXXA, the main IV line must be flushed with normal saline.  
If an infusion reaction occurs, Investigators are permitted to use concomitant medications or 
treatments deemed necessary to provide adequate patient care. Investigators should als o utilize 
the infusion reaction lab kit provided in  the Study Operations Manual to collect  additional blood 
specimens. In the case of a Grade 3 or 4 infusion reactions occurring during an infusion, the 
administration  of study  drug should  be immediately  discontinued,  and the affected  patient  should 
be treated according to the clinical trial siteâ€™s protocol for infusion reactions (e.g., monitoring, 
administration of antihistamines, corticosteroids, fluids and epinephrine, as clinically indicated).  
10.7 Study  Drug  Accountability  
Study drug will only be used as directed in the protocol. Study personnel will account for all 
vials  of study drugs  received, dispensed, and used for each patient, and vials  returned. The date 
and time of reconstitution and dilution will be recorded. Used vials should be traceable back  to 
the patient.  The Investigator  is responsible  for the study  drug accountability,  reconciliation,  and 
record maintenance. Refer to the Study Operations Manual for additional instructions.  
10.8 Study  Drug  Handling  and Disposal  
Unused, partially used and empty vials will be stored until the Sponsor or Sponsorâ€™s 
representative  instructs  the site to return  or dispose  of the vials.  Unused  supplies  will be returned 
or disposed of using appropriate documentation according to International Conference on 
Harmonization -Good Clinical Practice (ICH -GCP), local requirements, applicable Occupational 
Safety and Health Administration and Environmental Protection Agency regulations, and 
applicable study -specific procedures.  Refer to the Study Operations Manual for additional 
instructions.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  48 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
11. ASSESSMENT  OF EFFICACY  
11.1 Activity Assessment  
11.1.1  Serum  Uric Acid  Assessment  
The primary  endpoint  of this study  is the comparison  in the percentage  of patients  on SEL-212 
vs. KRYSTEXXA  who achieve and maintain reduction of SUA  < 6 mg/dL for  at least 80% of 
the time during Treatment Period 3 and Treatment Period 6.  
Serum  samples  for measurement  of SUA  will be collected  according  to the schedules  described 
in Section 20. Methods used for processing samples and for measurement of SUA levels are 
described in the Study Operations Manual.  
11.2 Gout  Assessment  
11.2.1  Gout Flare  Assessment  
Gout  flare will be assessed  as part of TEAE  collection  with severity  determined  as described  in 
Section 12.2.2.3 . 
11.2.2  Joint  Assessment  
Tender and/or swollen joints will be counted. The following joints will be assessed: 
metacarpophal angeal,  proximal  interphalangeal,  and distal  interphalangeal  joints  of the hands; 
the metatarsophalangeal and interphalangeal joints of the feet; shoulder, elbow, wrist, knee, 
ankle, tarsus, sternoclavicular, and acromioclavicular joints.  
11.3 Health  Questionna ires:  Patient  Reported  Outcomes  and Quality  of Life 
Assessment  
11.3.1  Health  Assessment  Questionnaire -Disability  Index  (HAQ -DI) 
The HAQ -DI will be administered  according  to the schedules  described  in Section  20. 
 
The HAQ -DI, which includes the patient  global assessment  and pain scale, is an instrument  that 
assesses  fine movements  of the upper  extremity,  locomotor  activities  of the lower  extremity,  and 
activities that involve both the upper and  lower extremities. Standard scoring takes into account 
the use of aids  and devices  or assistance from another person. There are 20  items  in 8 categories 
that represent a comprehensive set of functio nal activities: dressing, rising, eating, walking, 
hygiene, reach, grip, and usual activities. The stem of each item assesses a patientâ€™s functional 
ability using their usual equipment during the past week. Each category contains at least 2 
specific sub -category questions. For example, under the category â€œwalking,â€ patients are asked 
about their ability to walk outdoors on flat ground and to climb up 5 steps.  
11.3.2  Provider  Global  Assessment  of Disease  Activity  
The Provider  Global  Assessment  of Disease  Activity  (PrGA)  will be conducted  according  to the 
schedules described in Section 20. The PrGA will be administered to assess the severity of the  
PROPRIETARY AND  CONFIDENTIAL  PAGE  49 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
patientâ€™s  disease  on a scale  from  0 (patient  feels  â€œvery  wellâ€)  to 100 (patient  feels  â€œvery  poorâ€). 
Lower scores indicate less severe disease.  
11.3.3  Short  Form Health  Survey 36  (SF-36) 
The SF-36 will be administered  according  to the schedules  described  in Section 20. 
 
The SF -36 is a 36-item scale constructed  to survey  health  status  and quality  of life ( Ware 1992 ). 
The SF -36 assesses 8 health concepts: limitations in physical activities because of health 
problems; limitations in social activities because of physical or emotional problems; limitations 
in usual role activities beca use of physical health problems; bodily pain; general mental health 
(psychological distress and well -being); limitations in usual role activities because of emotional 
problems;  vitality  (energy  and fatigue);  and general  health  perceptions.  The standard  form of the 
instruments asks for patients to reply to questions according to how they have felt over the 
previous week.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  50 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
12. ASSESSMENT  OF SAFETY  
12.1 Safety  Parameters  
12.1.1  Demographic/Medical  History  
Demographic  and significant  medical  history  will be documented according  to the schedules 
described in Section 20. Medical history will be recorded up to the time of dosing.  
12.1.2  Concomitant  Medications  and Procedures  
Concomitant  medications  and procedures  will be documented  according  to the schedules 
described in Section 20. 
12.1.3  Vital  Signs  
Vital  signs  will be documented  according  to the schedules  described  in Section 20. 
 
Vital  signs  will include  systolic  blood  pressure  (mmHg),  diastolic  blood  pressure  (mmHg),  pulse 
(beats per minute, bpm), respiratory rate (breaths per minute), and temperature (Â°C). Blood 
pressure and heart rate will be recorded after at least 5 minutes of rest in a sitting position.  
12.1.4  Electrocardiogram  (ECG)  
A standard 12 -lead ECG  will be  performed according  to the  schedules  described  in Section  20. 
 
12.1.5  Weight  and Height  
Weight (kg) and height (cm) will be performed according to the schedules described in 
Section  20. Height  will be measured  at Screening  only.  Weight  will be used to calculate  study 
drug dosage as described in Section 10.4. 
12.1.6  Physical  Examination  
Physical  examinations  will be conducted  according  to the schedules  described  in Section  20. 
Breast, rectal, and urogenital exams are not required unless warranted based on the clinical 
judgment of the patientâ€™s medical history or current medical condition. The physical exam 
should be done by a physician or physi cianâ€™s assistant or similarly qualified individual.  
12.1.7  Tophus  Assessment  
Assessment  of the presence  of tophi  will be conducted  according  to the schedules  described  in 
Section 20. Patients will be stratified according to the presence of tophi (yes/no).  
At the time of tophus assessment ( Section 20), selected investigational sites wil l photograph 
tophi  on the hands  and feet in a subset  of subjects  for illustrative  purposes.  Detailed  procedures 
for conducting the photography are provided in the Study Operations Manual.  
12.1.8  Laboratory Assessments  
All laboratory  assessment  will be conducted  according  to the schedules  described  in Section  20. 
Procedures for processing samples are included in the study operations manual.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  51 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
12.1.8.1  Hematology  
Hematology  assessments  will include  white  blood  cells (WBC)  count  with differential,  red blood 
cell (RBC)  count, hematocrit (Hct), hemoglobin (Hgb), mean  corpuscular volume (MCV), mean 
corpuscular hemoglobin  (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell 
distribution width (RDW), platelet (Plt) count, mean platelet volume (MPV).  
12.1.8.2  Blood  Chemistry  
Clinical chemistry assessments will include alkaline phosphatase, alanine aminotransferase 
(ALT),  aspartate  aminotransferase  (AST),  total bilirubin,  blood  urea nitrogen  (BUN),  creatinine, 
fibrinogen, glucose (fasting), phosphorous, and electrolytes (sodium, potassium, chloride,  
bi-carbonate,  phosphate,  and magnesium).  
 
The following  clinical  laboratory  assessments  will be conducted  only during  Screening  to 
determine eligibility for study participation: anti -PEG antibodies and G6PD.  
12.1.8.3  Lipids  
Lipid  assessments  will include  total cholesterol,  high-density  lipoprotein  (HDL),  low-density 
lipoprotein (LDL), and triglycerides.  
12.1.8.4  Coagulation  
Coagulation  assessments  will include  prothrombin  time (PT),  activated  partial  thromboplastin 
time (aPTT), international normalized ratio (INR).  
12.1.8.5  Urinalysis  
Urinalysis  will include  assessment  of urinary  protein,  albumin,  creatinine,  pH, specific  gravity, 
blood, glucose, ketones, bilirubin, leukocyte, esterase, WBC, RBC, crystals, casts (cast types), 
epithelial cells (renal and nonrenal), bacteria, mucus, and yeast.  
At Screening  only,  urine  will be collected  for pregnancy  testing  (Section  12.1.8.8 ). 
 
12.1.8.6  Anti -Drug -Antibodies  
A blood  sample  for assessment  of development  of anti-drug-antibodies  will be collected for 
possible future analysis.  
12.1.8.7  Serology  
Serology screening will include human immunodeficiency virus (HIV) antibodies 1 and 2, 
hepatitis -B surface  antigen  (HBsAg),  and hepatitis -C antibody  (HCVAb).  If HCVAb  is positive, 
then HCV virus level will be determined.  
12.1.8.8  Pregnancy Screen  
Samples  for urine pregnancy  testing  (hCG)  will be obtained.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  52 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Female partners of male patients who are of childbearing potential are required to practice an 
acceptable form of birth control to  continue in the study  and for 30 days  after the last  study drug 
administration. Male patients of reproductive potential who are having intercourse with female 
partners  of childbearing  potential  must  agree  to use 2 forms  of contraception,  1 of which  must  be 
a barrier method, during the study and for 90 days after the last study drug administration.  
Acceptable  barrier  methods  include  a condom  and diaphragm.  Acceptable  forms  of birth  control 
for female partners of childbearing potential are non -hormonal and hormonal intrauterine 
devices, hormonal birth control pills, hormonal birth control patches, hormonal birth control 
injections, hormonal birth control implants. Spermicide used alone is not an acceptable method 
and must  be used with another  acceptable  form  birth control  method. Abstinence  is acceptable  if 
consistent with the patientâ€™s nor mal lifestyle.  
If a patient  becomes  pregnant  after she begins  taking  study  drug,  the procedures  in 
Section 12.2.2.7  should be followed.  
12.1.8.9  Definition  of Childbearing  Potential  and Acceptable  Contraceptive  Methods 
A woman is considered of childbearing potential (i.e., fertile), following menarche and until 
becoming post-menopausal unless  permanently sterile. Permanent sterilization methods  include 
hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.  
A postmenopausal state is defined as no menses for > 24 months without an alternative medical 
cause.  A high follicle  stimulating  hormone  (FSH)  level  in the postmenopausal  range  may be used 
to confirm a post -menopausal state in women not using hormonal contraception or hormonal 
replacement therapy. However, in the absence of > 24 months of amenorrhea, one conf irmatory 
FSH measurement must be obtained or documented.  
For female  partners  of childbearing  potential,  the following  methods  of contraception,  when  used 
consistently and correctly, are considered reliable for participation in the study:  
â€¢ Combined  (estrogen  and progestogen  containing)  hormonal  contraception  associated  with 
inhibition of ovulation: oral, intravaginal, or transdermal  
â€¢ Progestogen -only hormonal  contraception  associated  with inhibition  of ovulation:  oral, 
injectable or implantable  
â€¢ Intrau terine  device  (IUD)  
â€¢ Intrauterine  hormone -releasing  system  (IUS)  
â€¢ Bilateral  tubal;  occlusion  
â€¢ Vasectomized  partner  (provided  that partner  is the sole sexual  partner  and that 
vasectomized  partner  has received  medical  assessment  of the surgical  success)  
â€¢ Sexual  abstinence  (refraining  from  heterosexual  intercourse  during  the entire  study 
period; the reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the clinical study and the preferred and usual lifestyle of the patient)  
PROPRIETARY AND  CONFIDENTIAL  PAGE  53 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
12.1.9  Premedication  Regimen  
Refer  to Section  10.5 for procedures  about  premedication  regimens  to prevent  infusion 
associated reactions and gout flare.  
12.2 Adverse  and Serious  Adverse  Events  
12.2.1  Definition  of Adverse Events  
Definitions  in this section  are in accordance with  21 CFR 312.32.  
 
12.2.1.1  Adverse  Event  (AE)  
An AE is any untoward  medical  occurrence  associated  with the use of a drug (i.e., study  drug)  in 
humans, whether or not considered drug related. An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a drug and does not imply any judgment about causality. An AE can 
arise  with use of any drug or medicinal  product. A  treatment -emergent  AE (TEAE)  is an AE that 
starts o r worsens at any time after initiation of study drug on Day 0 of Treatment Period 1 until 
the End of Study Visit (30 days after completion of the last dose of study drug).  
Patients will be considered enrolled in the study upon signing the ICF. During the S creening 
Phase (from time informed consent is signed to immediately before dosing) any clinically 
significant changes in the patientâ€™s health will be recorded in the patientâ€™s medical history and 
will not be considered  as AEs.  AEs will be collected  from  the time the patient is  dosed  (infusion 
is started) until the end of the End of Study Visit. SAEs will be collected from the time the 
patient signs informed consent until the End of Study Visit.  
12.2.1.2  Serious  Adverse  Event  (SAE)  
An SAE  is any AE that occurs  irrespective  of study  treatment  assignment,  if it satisfies  any of 
these criteria:  
â€¢ Results  in death;  
â€¢ Is life -threatening;  
â€¢ Requires  inpatient  hospitalization  â‰¥ 24 hours  or prolongs  existing  hospitalization;  
â€¢ Results  in persistent  or significant  disability  or incapacity  or substantial  disruption  of the 
ability to conduct normal life functions;  
â€¢ Is a congenital  anomaly or birth defect;  
â€¢ Is an important medical event that, based  upon appropriate medical judgment,  may 
jeopardize the  patient  or patient  and may require  medical  or surgical  intervention  to 
prevent one of the outcomes listed above.  
 
12.2.1.3  Suspected  Adverse  Reaction  
A suspected adverse reaction is an AE for which there is a reasonable possibility that the drug 
caused  the AE. For the purposes  of IND safety  reporting,  â€œreasonable  possibilityâ€  means  there  is 
evidence to suggest a causal relationship between the drug and the AE. Suspected adverse  
PROPRIETARY AND  CONFIDENTIAL  PAGE  54 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
reaction  implies  a lesser  degree  of certainty  about  causality  than adverse  reaction,  which  means 
any AE caused by a drug.  
12.2.1.4  Unexpected  Adverse  Events  and Unexpected  Suspected  Drug  Reaction  
An AE or suspected  adverse  reaction  (an AE where  there  is a reasonable  possibility  that the  drug 
caused the event; suspected drug related) is considered â€œunexpectedâ€ if it is not listed in the  
SEL-212 Investigatorâ€™s  Brochure  or is not listed  at the specificity  or severity  that has been 
observed.  
12.2.1.5  Infusion  Reactions  / Adverse  Events  of Special  Interest  
A study drug -related AE that occurs within 24 hours after initiation of study drug infusion will 
be assessed as an infusion reaction. An infusion reaction suspected to be anaphylaxis will be 
assessed  according  to the clinical  criteria  for the diagnosis  of anaphylaxis  based  on the National 
Institute of Allergy and Infectious Diseases (NIAID) / Food Allergy & Anaphylaxis Network 
(FAAN) Symposium criteria ( Sampson 2006 ). 
Infusion reactions will be managed and  treated as desc ribed below. In addition to premedication 
with antihistamines  and steroids  (Section  10.5.2 ), the following  steps  will be implemented  in this 
protocol to either reduce the risk of infusion reactions or manage infusion reactions.  
â€¢ Patients  with immunoreactivity  to PEG will be ineligible  for the study  
â€¢ Patients  with prior  exposure  to uricase  therapy  will be ineligible  
â€¢ Patients  with a history  of anaphylaxis  or severe  allergic  reactions,  angioedema,  or 
previous infusion reactions will be excluded from the trial.  
â€¢ Study  drug will be administered  at controlled  rates  only in a healthcare  setting  and by 
healthcare providers  sufficiently  equipped  and prepared to  manage  infusion  reactions 
including anaphylaxis.  
â€¢ In case of infusion  reaction,  sites will perform  specific  assessments  as specified in  the 
Study Operations Manual.  
â€¢ Each  patient  will be observed  for infusion  reactions  after dosing  of study  drug in the 
clinic for approximately 1 hour  after the end of study drug infusion. Patients  will be 
informed  about  the signs  or symptoms  of infusion  reactions  and will be instructed  to 
notify the Investigator immediately if they believe they are experiencing a reaction.  
â€¢ Each  patient  shall remain  for a minimum  of 1 hour after the completion  of infusion  of 
study drug for a period of safety observation.  
â€¢ Only sites with immediate  capability  to appropriately  respond  to a reaction  of this 
severity will be allowed to participate  in the trial to reduce  the risk to  any patient.  
 
Adverse  events  of special  interest  (AESI)  will be recorded  specifically  for occurrences  of: gout 
flares,  infections,  viral infections,  interstitial  lung disease,  stomatitis,  infusion -related  reactions 
including anaphylaxis, malignancies, renal failure; and the following lab tests, if deemed  
PROPRIETARY AND  CONFIDENTIAL  PAGE  55 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
clinically  significant  by the PI: hyperlipidemia,  worsening  of renal  function  tests,  proteinuria, 
and leukopenia.  
12.2.2  Recording  Adverse  Events  
Patients will be encouraged to spontaneously report any changes in health from the time of 
signing  the ICF through  completion  of the study.  Study  staff will also inquire  about  any changes 
in the patientâ€™s health.  
All AEs will be recorded  in the source  document  and the CRF.  It is the responsibility  of the 
Investigator to review all documentation (e.g., hospital progress notes, laboratory, and 
diagnostics reports) for the presence of AEs and for a complete evaluation of known AEs.  
At minimum for each AE, the Investigator will evaluate and report the event 
name/term/description,  onset  (date  and time),  resolution  (date  and time),  event severity/intensity, 
relationship  to study  drug,  action  taken in  regard  to study  drug,  whether  the event  is an SAE,  and 
whether or not it caused the patient to discontinue the study. The event time is only required 
while the patient is in the clinic.  
During the Screening Phase (from time informed consent is signed to immediately before 
dosing)  any clinically  significant  changes  in the patientâ€™s  health  will be recorded  in the patientâ€™s 
medical history and will not be considered as AEs.  
12.2.2.1  Adverse  Event  Term/Name/Description  
The Investigator  will attempt  to establish  a diagnosis  of each AE based  on signs,  symptoms, 
and/or other clinical information. In such cases, the diagnosis will be the AE term used to 
document the AE/SAE and not the individual signs/ symptoms.  
12.2.2.2  Relationship  to Study  Drug  
The Investigator is obligated to  assess the relationship between study drug and  the occurrence of 
each AE. The Investigator will use clinical judgment to determine the relationship. Alternative 
causes,  such as natural  history  of the underlying  diseases,  concomitant  therapy,  other  risk factors, 
and the temporal relationship of the event to the study drug will be considered and investigated. 
The Investigator will also consult the SEL -212 Investigatorâ€™s Brochure and/or Product 
Information for marketed products in the determination of his/her assessment.  
The Investigator  will assess  causality  as to whether  the event  is related  or not related  to study 
drug based on the following definitions:  
â€¢ Not Related:  If no valid  reason  exists  for suggesting  a relationship  to study  drug or the 
AE was more likely explained by causes other than study drug.  
â€¢ Unlikely  to be Related:  Onset  of the event  has a reasonable  temporal  relationship  to study 
drug administration and although a causal relationship is unlikely, it is biologically 
plausible.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  56 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
â€¢ Possibly  Related:  Onset  of the event  has a strong  temporal  relationship  to administration 
of the study drug and a causal relationship is biologically plausible  
â€¢ Related: The study drug dosing and AE were closely related in time and the AE may be 
explained  by exposure  to study  product:  e.g., known  pharmacological  effect  or recurrence 
on re -challenge.  
 
There may be situations, particularly when an SAE has occurred, where the Investigator has 
minimal information to make an assessment in an initial SAE report. However, it is very 
important that the Investigator always makes an assessment of causality for e very SAE prior to 
transmission  of the SAE  report.  The Investigator  may change  his/her  opinion  of causality  in light 
of follow -up information, amending the SAE report accordingly. Any assessment of causality 
made by the Investigator should also be documente d in the patientâ€™s source medical record.  
12.2.2.3  Adverse  Event  Intensity/Severity  Grading  
AEs will be classified  according  to the Rheumatology  Common  Toxicity  Criteria,  version  2.0 
(Woodworth 2007 ). Additional details of the criteria can be found in the study operations 
manual.  
â€¢ Grade 1 (mild): AE that is usually  transient of short duration; or involves mild or minor 
symptoms which are of marginal clinical relevanc e; or is asymptomatic consisting of 
clinical  or diagnostic  observations  alone;  no intervention  or only minimal  treatment  with 
non-prescription intervention was required. The event does not generally interfere with 
usual activities of daily living.  
â€¢ Grade 2 (moderate): AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living (e.g., shopping, 
laundry,  transportation,  or ability  to conduct  finances),  causing  discomfort  but poses  no 
significant or permanent risk or harm to the patient.  
â€¢ Grade  3 (severe):  AE that is medically  significant/important  but not life-threatening;  may 
require brief hospitalization to prevent the event from worsening; interrupts usual 
activities of dail y living, or significantly affects clinical status, or may require intensive 
therapeutic intervention.  
â€¢ Grade 4 (life -threatening): An AE, and/or its immediate sequelae, which is associated 
with an imminent  risk of death  or which  is associated  with physical  or mental  disabilities 
that affect or limit the ability of a person to perform activities of daily living (eating, 
ambulation, toileting, etc.); disability may  be persistent or result in significant disability, 
incapacity or limitation of self -care activi ties. 
 
For an assessment  of anaphylaxis,  the clinical  criteria  for the diagnosis  of anaphylaxis  will be 
based on the NIAID/FAAN Symposium criteria ( Sampson 2006 ). 
12.2.2.4  Assessment  of Outcome  
The result  or conclusion  of the AE will  be assessed  and recorded  by the Investigator  as: 
â€¢ Fatal  
PROPRIETARY AND  CONFIDENTIAL  PAGE  57 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
â€¢ Not recovered/not  resolved  (the AE has not improved  or patient  has not recuperated).  
â€¢ Recovered/resolved  (the AE  has improved  or patient  has recuperated)  
â€¢ Recovered/resolved  with sequelae  (recuperated  but retained  pathological  conditions 
resulting from the AE)  
â€¢ Recovering/resolving  (the patient is  improving  but the AE has not yet resolved)  
â€¢ Unknown  (not known,  not observed, not  recorded, or refused)  
12.2.2.5  Action  Taken  with Study  Drug  
The action  taken with  reference  to study  drug will be assessed  by the investigator  as: 
â€¢ Dose not  changed  (dose  completed)  
â€¢ Dose  interrupted  (IV infusion  was temporally  modified  by temporarily  stopping  the 
infusion; slowing of the rate of infusion should also be classified as interrupted)  
â€¢ Drug  withdrawn  (IV infusion  was modified  through  termination  of the infusion)  
A response  option  for increasing or  decreasing  the dose is not an  available  course  of action  in 
this study.  
12.2.2.6  Laboratory  and Diagnostic  Abnormalities  as Adverse  Events  
Clinically significant abnormal laboratory findings or other abnormal diagnostic assessments 
(e.g.,  ECGs,  vital signs)  that are detected  in dosed patients  or that significantly  worsen  relative  to 
baseline in dosed patients will be reported as AEs. Clinical significance is based on the 
Investigatorâ€™s  judgment  but will typically  include  findings  that results  in study  withdrawal,  result 
in active management of the patient, or are associated with clinical signs and symptoms. Since 
the study requires patients with elevated or abnormal SUA levels, abnormal SUA levels will 
typically not be an AE unless judged by the I nvestigator as being more severe than expected for 
the patient.  
12.2.2.7  Pregnancy  
While pregnancy itself is not considered to be an AE, any pregnancy complication or elective 
termination of a pregnancy for medical reasons will be recorded as an AE and followed. Th e 
outcome  of all pregnancies  must  be followed  up and documented  even  if the patient is  no longer 
a study patient.  
The Investigator, or his/her designee, will collect pregnancy information on every female who 
becomes  pregnant  while  enrolled  in this study  and on every  female  partner  of a male patient  who 
becomes  pregnant while the male partner is  enrolled in  this study. The Investigator  will report  to 
the Sponsor  or Sponsorâ€™s  designee within  24 hours  of learning  of a patientâ€™s  or female partner  of 
a patientâ€™s pregnancy. In the case of a female partner of a male patient enrolled in the study 
becoming pregnant while the male patient is enrolled in this study, a separate pregnancy partner 
informed consent form will be completed by the patientâ€™s partner. The patient or female partner  
PROPRIETARY AND  CONFIDENTIAL  PAGE  58 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
of a patient  must  also be followed  to determine  the outcome  of the pregnancy.  Information  on the 
status of the mother and child will be forwarded to the Sponsor or Sponsor Designee, as 
appropriate. Follow -up on the child will be to the first well -child visit. Any premature 
termination of the pregnancy will be reported.  
A spontaneous abortion or congenital abnormalities/birth defects will be considered SAEs and 
will be reported as such. Furthermore, any SAE occurr ing as a result of a post -study pregnancy 
and is considered  reasonably related  to the study  drug by the Investigator,  will be reported  to the 
Sponsor.  
12.2.3  Reporting  Adverse  Events  
12.2.3.1  Adverse  Event  Reporting  Period  
The study period during which AEs must be reported is from the time the patient is dosed until 
the 30 days after the last infusion  of study  drug.  During  the Screening  Phase  (from  time informed 
consent is signed up to the time of dosing) any clinically significant changes in the patientâ€™s 
health wi ll be recorded in the patientâ€™s medical history and will not be considered as AEs.  
Investigators  are not obligated  to actively  seek AEs or SAEs  in former  study patients.  However, 
if the Investigator learns of any SAE, including a death, at any time after a patient has been 
discharged from the study, and he/she considers the event reasonably related to the study drug, 
the Investigator should promptly notify the Sponsor.  
12.2.3.2  SAE  Reporting  Procedures  
If SAEs occur, all Investigators should immediately, but not later than 24 hours of observing or 
learning  of the event,  complete  and fax the SAE form to Syneos  Health  and Pharmacovigilance.  
Facsimile  (for SAE only):   
 
Email  (for SAE only):   
 
The Investigator  will complete  the SAE  form  and provide  all case information  available  at the 
time of the initial report. The inves tigator must include the following mandatory case 
information:  
1. The patient  identification  number  
2. The event description  
3. The seriousness  criteria  
4. The Investigatorâ€™s  causality  assessment  
 
The reporting  Investigator  must  send the written  and signed  SAE  report  by facsimile  or email, 
within 24 hours of observing, notification of, or learning of the SAE to Syneos Health and 
Pharmacovigilance as described above. Follow -up information regarding an SAE and the 
supporting data, including laboratory findings and  discharge summaries, should be sent by  

PROPRIETARY AND  CONFIDENTIAL  PAGE  59 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
facsimile  or email  to Syneos  Health  and Pharmacovigilance within  24 hours  of receipt  of the 
information.  
If the Investigator  does not have  all information  regarding  an SAE,  the Investigator  will not wait 
to receive additional information before completing as much of the form as possible and 
notifying the safety group. The form will be updated when additional information is received.  
The Investigator  will always  provide  at minimum:  1) AE term or event  name/description,  
2) patient  identifier,  3) an assessment  of causality  (Section 12.2.2.2 ). 
 
12.2.3.3  Regulatory  Reporting  Requirements  for SAEs  
The Sponsor or Sponsor representative will report fatal or life -threatening SAEs that are 
unexpected suspected adverse reactions to  the relevant regulatory authorities within  7 calendar 
days, and non -fatal or life -threatening SAEs that are unexpected suspected adverse reactions 
within  15 calendar  days as Investigational  New  Drug  (IND) Safety  Reports,  in accordance  with 
21 CFR 312.32. Prompt notification of SAEs by the Investigator to the appropriate project 
contact  for SAE  receipt  is essential  so that legal  obligations  and ethical  responsibilities  towards 
the safety of other patients are met.  
12.2.3.4  Reporting  Safety  Information  to the IRB/IEC  
The Investigator,  or responsible  person  according  to local  requirements,  will comply  with the 
applicable local regulatory requirements related to the reporting of SAEs to the Institutional 
Review Board (IRB)/Ethics Committee (EC).  
All Investigators involved in studies with this drug will receive a copy of each IND Safety 
Report.  When  an Investigator  receives  an IND Safety  Report or other  safety  information  (e.g., 
revised Clinical Investigatorâ€™s Brochure/Investigatorâ€™s Brochure), the responsible person 
according to local requirements is required to promptly notify his or her IRB.  
12.2.4  Follow -up of Adverse  Events  
The Investigator  is required  to proactively  follow  each patient  and provide  further  information  in 
regards  to AEs and SAEs.  All AEs and SAEs  will be followed until  30 days after the last dose of 
study drug, resolution of the event, until the condition stabilizes, until the event is otherwise 
explained, or until the patient is lost to follow -up, whichever occurs earlier. Once resolved, the 
appropriate CRF entries and event reporting forms will be updated, as appropriate.  
All AEs and SAEs documented at a previous visit/contact  and designated as ongoing will be 
reviewed  at subsequent  visits/contacts.  The Investigator  will ensure  that follow -up includes  any 
supplemental investigations as may be indicated to elucidate the nature and/or causality of the 
AE or SAE. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  60 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
The Sponsor  or the Sponsorâ€™s  designee  may request  that the Investigator  perform  or arrange  for 
the conduct o f supplemental measurements and/or evaluations to elucidate as fully as possible 
the nature and/or  causality  of the AE or SAE.  The Investigator  is obligated  to assist.  If a patient 
dies during participation  in the study or during a recognized follow -up period, the Sponsor will 
be provided with a copy of any post -mortem findings, including histopathology.  
New or updated information will be recorded on the originally completed SAE forms, with all 
changes  signed  and dated  by the Investigator.  This information  will also be entered  into the CRF.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  61 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
13. STATISTICS  
Details  of the statistical  methods  outlined in  the protocol  for this study,  including  the hierarchical 
ordering  of the secondary  endpoints,  will be documented  in a Statistical  Analysis  Plan (SAP) that 
will be finalized prior to first patient randomized. The SAP may add additional exploratory 
analyses; modifications to the planned analyses will be identified as such in the SAP.  
13.1 Sample  Size Determination  
The primary ef ficacy criterion in this study is defined as the percentage of subjects who achieve 
and maintain  reduction  of SUA  < 6 mg/dL  for at least 80% of the time during  Treatment  Period  3 
and Treatment Period 6.  
The percentage  of responders  according  to the above  criterion  is assumed  to be 65% in the 
SEL-212 arm and 44% in the KRYSTEXXA arm.  
Using the Chi -square test for comparison  between the SEL -212 arm and  the KRYSTEXXA arm, 
and considering  a one-sided  alpha=5%  and the statistical  power  of 80%,  results  in 69 subjects  per 
treatment group. Taking into account that some subjects may be excluded from the modified 
Intent -to-Treat (mITT) analyses ( Section 13.2.4 ), 75 subjects per treatment group will be 
randomized. For the sample size estimation, Chi -square test, instead of the Cochran -Mantel - 
Haenszel test, is used although the randomization will be stratified for tophus presen ce (yes/no) 
as there is  no valid assumption of the distribution of this  stratification variable within the eligible 
subject population.  
Sample  size calculations  were  performed  with the software  package  nQuery  AdvisorÂ®  Sample 
Size Calculator V. 8.2.1.0.  
13.2 Analysis Populations  
13.2.1  Screened  / Randomized  Set 
The Screened  Set will include  all patients  who signed  an informed  consent.  The Randomized  Set 
will include all patients randomized.  
13.2.2  Safety  Set (SS) 
The Safety Set will include all patients who were administered any amount of study medication. 
Patients  will be analyzed  according  to treatment  received.  The SS will be used for all analyses  of 
safety endpoints and for the presentation of patients in all patient listings.  
13.2.3  Intent -to-Treat  (ITT)  Set 
The Intent -to-Treat  (ITT)  Set will be used as the primary  population  for the analysis  of efficacy. 
The ITT Set will include all randomized patients. Patients will be analyzed according to 
randomized treatment.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  62 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
13.2.4  Modified  ITT (mITT)  Set 
The modified ITT (mITT) Set will include all randomized patients who were administered at 
least one complete dose of study medication and have at least one post -baseline assessment of 
SUA.  Patients  will be analyzed  according  to randomized  treatment.  The mITT  will also be used 
for analyses of efficacy endpoints.  
13.2.5  Per Protocol  Set 
The Per Protocol Set (PPS) will include all patients who 1) were administered any amount of 
study medication, and 2) have completed at least 65% of the study dosing visits with or withou t 
receiving study drug (eg  at least 4 of 6 TP  Day 0 visits  for patients  receiving SEL -212 or at least 
8 of 12 TP Day 0 or Day14  visits  for patients  receiving Krystexxa)  unless  early  termination  from 
the study occurred after study drug withdrawal due to meeting stopping rules or due to an 
adverse event, or due to PI discretion (for example where at least one pre -dose SUA was >6 
mg/dL in the Krystexxa arm and patient was discontinued from study tre atment), and 3) who 
have no major Protocol deviations ( Section 13.3) affecting the primary efficacy assessments.  
Patients  will be analyzed  according  to randomized  treatment.  
 
13.3 Protocol  Deviat ions 
All protocol deviations related to study inclusion or exclusion criteria, conduct of the trial,  
patient management, dosing, and sampling procedures or patient assessment will be listed. The 
list of protocol deviations will be reviewed by the Sponsor, the principal investigator, the study 
statistician  and the study  pharmacokineticist  and finalized  before  database  lock. Determination  of 
whether the deviation is major or minor will be based on the biasing impact of the deviation on 
the safety and efficacy data.  
13.4 Efficacy  Analyses  
13.4.1  Primary  Efficacy  Endpoint  
The primary  efficacy  endpoint  is defined  as: 
 
â€¢ Comparison in the percentage of patients on SEL -212 vs. KRYSTEXXA who achieve 
and maintain  reduction  of SUA  < 6 mg/dL  for at least 80% of the time during  Treatment 
Period 3 and Treatment Period 6  
 
The primary estimand will take into consideration the treatment policy strategy, ie, Treatment 
Period 6 (and also Treatment Period 3) assessments will be considered for all subjects in ITT 
independently  whether  the subject  has completed  the study  treatment  or has terminated  early  the 
study  treatment.  Additionally,  the estimand  based  on the while -on-treatment  strategy  for dealing 
with study  treatment  terminators  will be defined.  For all used estimands  of the primary  efficacy, 
the estimator  for the comparison  between  the treatment  groups  is defined  as the difference  in the 
proportion of responders between subjects receiving SEL -212 versus those receiving 
KRYSTEXXA during Treatment Periods 3 and 6. The statistical testing will be performed 
confirmatory using the Cochran -Mantel -Haenszel (CMH) test â€“ considering the randomization  
PROPRIETARY AND  CONFIDENTIAL  PAGE  63 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
stratum  of tophus  presence  (yes/no) â€“ with a one-sided  type 1 error  rate Î± = 5%. In addition , 90% 
two-sided confidence intervals for the overall treatment difference between SEL -212 and 
KRYSTEXXA treatment groups without stratification will be computed. The analysis of the 
estimands will be carried out based on  the ITT primarily. Supportive analy ses will be performed 
on the mITT and the PP. For each defined  estimand sensitivity analyses will be performed using 
different imputation approaches for missing values. Details of the applied approaches will be 
presented in the Statistical Analysis Plan.  
The SUA time curve will be used to estimate the proportion of time that the  SUA level is below  
6 mg/dL. Based on  the serum samples  collected during Treatment Periods  3 and 6, an estimate of 
the time with SUA  < 6 mg/dL  can be determined by  connecting  each two neighboring  data points 
with a straight line. If the SUA time curve goes above 6 mg/dL the linear interpolation method 
will be used to estimate the point in time at which the  SUA time curve intercepts the line  
between the last SUA value  < 6 mg/dL and the first value â‰¥ 6 mg/dL.  
The proportion of time that the SUA level is < 6 mg/dL will be computed by taking the ratio 
between  the time during  which  the SUA  level  remains  < 6 mg/dL  (if necessary,  using  the linear 
interpolation method) and th e entire time interval within Treatment Periods 3 and 6.  
Let T1 be the total time interval in hours for Treatment Period 3 of which W1 hours is the time 
interval during which SUA level is < 6 mg/dL. Similarly, for Treatment Period 6, assume T2 is 
the total time interval  in hours  of which  W2 hours  is the time  interval  during  which  SUA  level  is 
< 6 mg/dL. For a subject  to be considered  a responder, the proportion of  time that the SUA  level 
is < 6 mg/dL during  Treatment  Periods  3 and 6 must  be at least 80%.  The proportion  of time that 
the SUA level is < 6 mg/dL, i.e., percentage of non -hyperuricemic time, is calculated using the 
following formula:  
ð‘ƒð‘Ÿð‘œð‘ð‘œð‘Ÿð‘¡ð‘–ð‘œð‘›  =  
ð‘Š1 + ð‘Š2 
ð‘‡1 + ð‘‡2 Ã— 100 
 
A logistic  regression  model  controlling  for the distribution  of baseline  characteristics  will be 
performed as supportive analysis.  
Summary  tables  of the percentage  of responder  (subjects  who achieve  and maintain  reduction  of 
SUA < 6 mg/dL for at least 80% of the time) in each treatment period will be provided by 
treatment group.  Additionally,  a summary  table  with the total time a subject  has SUA  values  < 6 
mg/dL will be provided for each treatment period by treatment group.  
Summary  tables  of the actual  values and change  from  baseline  for SUA  results  will be provided 
for each scheduled sampling time point by treatment group.  
Additionally,  mean  SUA  level,  reduction  in mean SUA  and percent  reduction  in mean SUA  from 
baseline during Treatment Period 3 or Treatment Period 6 will be presented by treatment group.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  64 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
â€¢ Mean SUA  level is defined as  the area under the SUA  time curve (computed using the 
linear  trapezoidal  rule during  Treatment  Periods  3 and 6) divided  by the corresponding 
time interva l. 
â€¢ Reduction  in mean  SUA  is computed  by subtracting  baseline SUA  level  from  mean  SUA 
during Treatment Period 3 and 6.  
â€¢ Percent  reduction  in the mean SUA  from  baseline  is computed  as the mean SUA  level 
during  Treatment  Periods  3 and 6 minus  baseline SUA  level  divided  by baseline SUA 
level multiplied by 100  
 
13.4.2  Secondary  Efficacy  Endpoints  and Analyses  
The secondary  endpoints  of this  study are: 
â€¢ Comparison in the percentage of patients on SEL -212 vs. KRYSTEXXA who achieve 
and maintain  reduction  of SUA  < 6 mg/dL  for at least 80% of the time during  Treatment 
Period 6  
â€¢ Comparison in the percentage of patients on SEL -212 vs. KRYSTEXXA who achieve 
and maintain  reduction  of SUA  < 6 mg/dL  for 100%  of the time during  Treatment  Period 
6 
â€¢ Comparison in the percentage of patients on SEL -212 vs. KRYSTEXXA who achieve 
and maintain  reduction  of SUA  < 6 mg/dL  for at least 80% of the time during  Treatment 
Period 3  
â€¢ Comparison in the percentage of patients on SEL -212 vs. KRYSTEXXA who achieve 
and maintain  reduction  of SUA  < 6 mg/dL  for 100%  of the time during  Treatment  Period 
3 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  in pre -dose SUA  values  
> 6 mg/dL  during  Treatment  Periods  2-6. The pre-dose SUA  is collected  on the dosing 
day prior to the dosing administration or it  is collected  at the visit where dosing would 
have occurred had the patient not been previously withdrawn from study drug.  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  in health 
questionnaires  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of gout flare incidence  per 
3-month period (Treatment Periods 1 -3 and Treatment Periods 4 -6) 
â€¢ Comparison  between  patients  on SEL -212 vs. KRYSTEXXA  of gout flare frequency  per 
3-month period (Treatment Periods 1 -3 and Treatment Periods 4 -6) 
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  from 
Baseline to Treatment Period 6 in number of tender joints  
â€¢ Comparison  between  patients  on SEL-212 vs. KRYSTEXXA  of the change  from 
Baseline to Treatment Period 6 in number of swollen joints  
 
All statistical tests in secondary endpoints for the comparison between SEL -212 and 
KRYSTEXXA  will be performed  using  one-sided  tests at a type 1 error  rate level  of Î±=5%.  In 
addition, 90% confidence interval s for treatment differences between SEL -212 and  
PROPRIETARY AND  CONFIDENTIAL  PAGE  65 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
KRYSTEXXA  treatment  groups  will be computed.  The efficacy  analyses  will be carried  out 
based on the ITT and PP Sets. mITT  analyses will be performed if appropriate.  
Summary  table  of the number  and percentage  of subjects  who achieve  and maintain  reduction  of 
SUA < 6 mg/dL for at least 80% of the time during Treatment Period 6 will be provided by 
treatment group.  The compariso n between  the treatment groups will be performed similar  to the 
primary efficacy endpoint using a CMH -test considering the randomization stratum.  
Summary  table  of the number  and percentage  of subjects  who achieve  and maintain  reduction  of 
SUA < 6 mg/dL for 100% of the time during Treatment Period 6 will be provided by treatment 
group. The comparison between the treatment groups will be performed similar to the primary 
efficacy endpoint using a CMH -test considering the randomization stratum.  
Summary table of the number and percentage of subjects with pre -dose SUA values  > 6 mg/dL 
during  Treatment  Periods  2-6 will be provided  by treatment  group.  The comparison  between  the 
treatment groups will be performed similar to the primary efficacy endpoi nt using a CMH -test 
considering the randomization stratum.  
For the health questionnaires, comparison with regards to change from baseline in health 
questionnaires will be performed using an ANCOVA with the respective change from baseline 
value  as dependent  variable,  treatment  group and  the randomization  stratum as  independent  fixed 
factors and the baseline value as independent covariate.  
For each health questionnaire, summary tables of total scores or domain scores and subscale 
scores  will be provided  for each scheduled  assessment  time by treatment  group.  Additionally, 
summaries of the changes from baseline will be provided.  
The number  and percentage  of subjects  reporting  gout flares  per 3-months  period  and overall,  i.e. 
Treatment Periods 1 -3 and Treatment Periods 4 -6 and Period 1 -6, will be summarized by 
treatment group and will be tested using a CMH -test considering the randomization stratum.  
The frequency  of gout flares  will be summarized  per 3-months  period  and overal l and  by severity 
for each treatment and will be compared using ANOVA model with presences of tophus and 
treatment as fixed factors. In addition for periods 4 -6 and 1 -6, poisson regression model will be 
used with number of gout flares as independent variab le, treatment and presence of tophus as 
fixed factor, and length of follow -up for each corresponding treatment period as covariate.  
Comparison with regards to change of tender joints from baseline will be performed using an 
ANCOVA with the change from base line value as dependent variable, treatment group and 
randomization stratum as independent fixed factors and the baseline number of tender joints as 
independent covariate. In case of non -normality the non -parametric Wilcoxon test will be used 
for the compa rison  between  the treatment  groups.  Summary  tables  of the number  of tender  joints  
PROPRIETARY AND  CONFIDENTIAL  PAGE  66 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
for each assessment  timepoint  and for the change  from  baseline  will be provided  by treatment 
group.  
Comparison with regards to change of swollen joints from baseline will be performed using an 
ANCOVA with the change from baseline value as dependent variable, treatment group and 
randomization  stratum  as independent  fixed  factors  and the baseline  number  of swollen  joints  as 
independent covariate. In case of  non-normality, the non -parametric Wilcoxon  test will be used 
for the comparison between the treatment groups. Summary tables of the number of swollen 
joints for each assessment timepoint and for the change from baseline will be provided by 
treatment group.  
13.4.3  Subgroup  Analyses  
In the event  of a prolonged  gout flare which is  not successfully  managed,  Investigators  will most 
likely treat patients with corticosteroids which will have a downstream effect on the duration of 
flares, swollen/tender jo int counts and QOL assessments. In order to better extrapolate the 
results, a subgroup analysis will be conducted for patients who receive â€œadditional gout flare 
treatmentâ€ in  each arm for these objectives. Details  of this  subgroup analysis  will be  provide d in 
the SAP.  
13.5 Safety  Analyses  
13.5.1  Extent  of exposure:  
Frequency  counts  of number  of patients  who received  all doses (i.e.,  completed  study  treatment) 
and descriptive statistics of doses and total cumulative doses by treatment group (SEL -212 or 
KRYSTEXXA) will be presented.  
13.5.2  Adverse  Events  / Adverse  Drug  Reactions:  
All AEs will be coded  and grouped  into Preferred  Terms  (PT) by System  Organ  Class  (SOC), 
using the most recent MedDRA Version. All AEs will be summarized by SOC and PT.  
An overall  summary  will be provided  of the number  and percentage  of patients  reporting  TEAEs, 
serious TEAEs, treatment -related TEAEs, AESIs, TEAEs leading to withdrawal, and TEAEs 
leading to death.  
The number and percentage of patients with TEAEs / serious TE AEs / TEAEs leading to 
withdrawal/treatment -related  TEAEs  will be summarized  by SOC  and PT for each treatment 
group (SEL -212 or KRYSTEXXA). AESIs will also be summarized.  
TEAEs  will also be summarized  by maximum  intensity  and causality.  
 
13.5.3  Laboratory Assessments  
Laboratory  data will be summarized  by the type of laboratory  test and will be presented  for each 
scheduled visit stratified by treatment group (SEL -212 or KRYSTEXXA). Normal reference  
PROPRIETARY AND  CONFIDENTIAL  PAGE  67 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
ranges and markedly  abnormal results will  be used in the summary of laboratory data. Data will 
be flagged  according  to the reference  limits  (High  or Low),  if applicable.  Changes  from  baseline 
will be presented for each post -baseline visit. Shift tables of the number of patients with 
low/normal/high values at each scheduled post -baseline visit compared to the low/normal/high 
categorization at baseline will be provided by treatment group (SEL -212 or KRYSTEXXA).  
13.5.4  Vital  Signs  
Summary  tables  of the actual  values  and changes  from baseline  will be provided  for each vital 
sign parameter at each scheduled visit by treatment group (SEL -212 or KRYSTEXXA).  
13.5.5  ECG  
For each 12 -lead ECG variable the actual value and the change from baseline will be 
summarized  for the scheduled  visits  by treatment  group  (SEL -212 or KRYSTEXXA).  
Frequency tables of abnormal clinically significant evaluations as well as the number and 
percentage  of patients  with noteworthy  QTcF/QTcB  values  (> 450, > 480 and > 500 ms) and of 
patients with noteworthy QTcF/QTcB changes from baseline (â‰¥ 30 but <60; â‰¥ 60 ms) will be 
provided.  
13.5.6  Tophus  Assessment  
For each tophus  assessment variable  (including  total number,  location,  palpation  and appearance) 
the actual value and the change from ba seline will be summarized for the scheduled visits by 
treatment group (SEL -212 or KRYSTEXXA).  
PROPRIETARY AND  CONFIDENTIAL  PAGE  68 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
14. DIRECT  ACCESS  TO SOURCE  DATA/DOCUMENTS  
Individual patient medical information obtained as a result of this study is considered 
confidential  and dis closure to third parties  other than  those noted below is prohibited. Upon the 
patientâ€™s  permission,  medical  information  may be given  to the patientâ€™s  personal  physician  or to 
other appropriate medical personnel responsible for the patientâ€™s welfare. Data generated as a 
result  of this study  must  be made  available  for inspection  upon  request  by representatives  of the 
US FDA, national and local health authorities, the Sponsor or its representatives, and by the 
IRB/EC (or equivalent).  
PROPRIETARY AND  CONFIDENTIAL  PAGE  69 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
15. QUALITY  CONTROL  AND  QUALITY  ASSURANCE  
15.1 Study  Monitoring  
In accordance with applicable regulations, ICH -GCP and procedures covering the study, a 
monitor will contact the site prior to the subject enrollment to review the protocol and data 
collection  procedures  with site staff.  In addition,  the monitor  will periodically  contact  the site, 
including conducting on -site visits at an appropriate frequency to ensure data quality and to 
ensure the safety and rights of subjects are being protected.  
The investigator  agrees to allow the monitor direct  access to all relevant documents and to 
allocate  his/her  time and the time of his/her  staff to the monitor  to discuss  findings  and any 
relevant issues.  
15.2 Audits  and Inspections  
To ensure  complian ce with Good  Clinical  Practices  and all applicable  regulatory  requirements, 
quality  assurance audits may occur during  the study or after the study is complete. Authorized 
representatives of the Sponsor, the CRO conducting the study, a regulatory authority, an IRB 
may visit the site to perform audits or inspections to examine all study -related activities and 
documents to determine whether these activities were conducted, and data were recorded, 
analyzed, and accurately reported according to the pro tocol, ICH -GCP, and any applicable 
regulatory requirements.  
If an audit or inspection occurs, the Investigator and institution agree to allow the 
auditor/inspector  direct  access  to all relevant  documents  and to allocate  his/her  time and the time 
of his/her  staff to the auditor/inspector to discuss findings and any relevant issues. The 
Investigator should contact the Sponsor immediately if contacted by a regulatory agency about 
an inspection.  
15.3 Protocol  Modifications  
The initial protocol as well as all protoco l amendments must be signed and dated by the 
Investigator  and approved  by the IRB prior  to implementation  of the original  protocol  and any 
amendment. The Principal Investigator must submit all protocol modifications to the IRB, as 
applicable for specific I nvestigators, or applicable local regulatory authority. The Sponsor or 
designee will submit protocol modifications to the FDA as needed.  
Departures  from  the protocol  will be determined  as allowable  on a case-by-case basis  or in event 
of an emergency  involving  subject  safety.  The Investigator  or other  physician  in attendance  must 
contact the Medical Monitor as soon as possible to discuss the circumstances of the emergency. 
The Medical Monitor, in concurrence with the Investigator, will decide whether the patient 
should continue to participate in the study. All protocol deviations and the reason for such 
deviations must be noted on the source document and in the CRF, and reported to the IRB as 
appropriate.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  70 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
16. ETHICS  AND  GOOD  CLINICAL  PRACTICE  COMPLIANCE  
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing,  conducting,  recording  and reporting  trials  that involve human  patients.  Compliance 
with this standard provides public assurance that the rights, safety, and well -being of study 
patients  are protected,  consistent  with the principles  that have  their origin  in the Declaration  of 
Helsinki ( World Medical Association 2013 ), and that the clinical trial data are credible.  
The study will be conducted under a US IND and all applicable US FDA and local laws and 
regulations  and Good  Clinical  Practice  Guidelines.  The Investigator  agrees  to conduct  the study 
in compliance with the current version of US Food Drug & Cosmetic Act, Section 21 CFR,  
Part 312, Subpart D (Responsibilities of Sponsor and Investigators), part 50 (Protection of 
Human Subjects), part 56 (Institutional Review Boards), the principles of the De claration of 
Helsinki, and with  the laws and regulations of the country in which the  research is conducted in 
order  to afford  the greatest  protection  to the individual.  The Investigator  must  fully  adhere  to the 
principles outlined in the â€œGuideline for Goo d Clinical Practiceâ€ International Conference on 
Harmonisation (ICH) Tripartite Guideline and, for studies conducted in the EU/European 
Economic Area (EEA) countries, the Investigator will ensure compliance with the EU Clinical 
Trial Directive [2001/20/EC] . 
This study will be conducted in full compliance with the Institutional Review Board (IRB) / 
Ethics Committee (EC) regulations in 21 CFR 56 and applicable local regulatory guidance,  in 
accordance  with ICH-GCP.  IRB/EC  approval  for the investigation  must  be obtained  before  the 
study is initiated. Initial IRB/EC approval, and all materials approved by the IRB/EC for this 
study including the patient consent form and recruitment materials must be maintained by the 
Investigator and made available for inspection.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  71 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
17. DATA  HANDLING  AND  RECORDKEEPING  
17.1 Data  Management  
17.1.1  Case  Report  Forms  
Data  for this study  will be recorded  via an EDC  system  using  eCRFs.  It will be transcribed  by 
the site from the paper source documents onto the eCRF.  
The information collected on eCRFs must be identical to the corresponding information 
appearing  in original source documents. There are no exceptions  to this rule. In general, source 
documentation  will be found  in a chart  maintained  by qualified  medical  person nel in a hospital, 
clinic, or physicianâ€™s office. (The eCRF is not considered as source data for this trial).  
Accurate and reliable data collection will be assured by verification and cross check of the 
eCRFs  against  the Investigatorâ€™s  records  by the study  monitor  (source  document  verification), 
and the maintenance of a drug dispensing log by the Investigator.  
As a matter of regulations, the Investigator is responsible for the accuracy  and authenticity of all 
clinical  and laboratory  data entered  onto eCRFs.  Prior  to submission,  each completed  eCRF  must 
be reviewed for accuracy by the Investigator, corrected as necessary, and then approved and e - 
signed. The Investigatorâ€™s e -signature serves to attest that the information contained on the 
eCRFs has been reviewed by the Investigator and is true and accurate.  
The eCRFs  should  be completed by  the Investigator  or a qualified designee  from  the site as soon 
as the data are available. Instructions for the completion of eCRFs will be provided.  
The eCRFs  will be considered  complete  when  all missing,  incorrect,  and/or  inconsistent  data 
have been accounted for.  
17.1.2  Retention  of Records  
An Investigator must maintain adequate records to include the disposition of the study 
medication(s) and adequate and accurate source do cumentation that record all observations and 
other  data pertinent  to the investigation  on each patient  in the study.  These  records  are to include 
the case report forms (CRFs), source documentation, and supporting data, including, for 
example, signed and da ted informed consent forms and medical records (including progress 
notes by the physician and/or other qualified medical personnel,  the patientâ€™s hospital and clinic 
chart[s], and the nursesâ€™ notes).  
The FDA  (21 CFR  Â§312.62[c])  states  that the Investigator  shall retain  the required  records:  
 
a. For a period  of 2 years  following  the date a marketing  application  is approved  for the 
drug for the indication for which it is being investigated; or  
b. If no application is to be filed or if the marketing appl ication is not approved for such 
indication,  until 2 years  after the investigation  is discontinued  and the FDA  is notified.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  72 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
If neither  a) nor b) applies,  then the Investigator  shall  retain  the required  records  for a minimum 
of 15 years after the completion or discontinuation of the study.  
For sites outside  the US, the Investigator  must  comply  with US FDA  regulations  and with the 
record  retention  policies  of the relevant  national  and local  health  authorities.  The Investigator 
must obtain the Sponsorâ€™s written permission before disposing of any records.  
If the Investigator retires, relocates, or for any reason withdraws from the study, then the study 
records  may be transferred  to an acceptable  person  or institution  with the written  approval  of the 
Sponsor.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  73 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
18. REPORTING  STUDY  RESULTS  AND  PUBLICATION  POLICY  
Following analysis of the data and upon request by the Investigator,  the Sponsor will  supply a 
listing of site -specific treatment assignments, tabulated data, and statistical analysis, as 
appropriate.  A summary  of the study  results  will be provided  to each Investigator  following  its 
release by  the Sponsor.  The Investigator  will acknowledge receipt  of any data listings  or study 
results.  
Guidelines  concerning  publicat ion of the results  of this clinical  study  are contained  within  the 
formal Clinical Study Agreement associated with this protocol.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  74 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
19. LIST  OF REFERENCES  
Becker  MA,  Schumacher  HR, Benjamin  KL, et al. Quality  of life and disability  in patients  with 
treatment -failure gout. J Rheumatol. 2009;36(5):1041 -1048.  
Brook RA, Forsythe A, Smeeding JE, Lawrence Edwards N. Chronic gout: epidemiology, 
disease  progression,  treatment  and disease  burden.  Curr Med Res Opin.  2010;26(12):2813 -2821.  
Campion  EW, Glynn  RJ, DeLabry  LO. Asymptomatic  hyperuricemia.  Risks  and consequences 
in the Normative Aging Study. Am J Med. 1987 Mar;82(3):421 -6. 
Chandratre  P, Roddy  E, Clarson  L, Richardson  J, Hider  SL, Mallen  CD. Health -related  quality  of 
life in gout: a systematic review. Rheumatology (Oxford). 2013;52(11):2031 -2040.  
Choi  HK, Mount  DB, Reginato  AM;  American  College  of Physicians;  American  Physiological 
Society. Pathogenesis of gout. Ann Intern Med. 2005 Oct 4;143(7):499 -516. 
Choi  H. Epidemiology  of crysta l arthropathy.  Rheum  Dis Clin North  Am. 2006  May;32(2):255 - 
73, v.  
Dalbeth  N, Schauer  C, Macdonald  P, et al. Methods  of tophus  assessment  in clinical  trials  of 
chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis. 
2011;70(4):597 -604. 
Edwards  NL, Sundy  JS, Forsythe  A, Blume  S, Pan F, Becker  MA.  Work  productivity  loss due to 
flares in patients with chronic gout refractory to conventional therapy. J Med Econ.  
2011;14(1):10 -15. 
 
Khanna  D, Fitzgerald  JD, Khanna  PP, Bae S, Singh  MK,  Neogi  T, et al. 2012  American  College 
of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and 
pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012a 
Oct;64(10):1431 -46. 
Khanna  D, Khanna  PP, Fitzgerald  JD, Singh  MK, Bae S, Neogi  T, et al. 2012  American  College 
of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory 
prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012b Oct;64(10):1447 -61. 
Krystexxa  Prescribing  Informa tion. Horizon  Pharma.  2018.  
 
Lim SY, Lu N, Oza A, et al. Trends  in gout and rheumatoid  arthritis  hospitalizations  in the 
United States, 1993 -2011. JAMA. 2016;315(21):2345 -2347.  
Luk AJ, Simkin  PA. Epidemiology  of hyperuricemia  and gout.  Am J Manag  Care.  2005 
Nov;11(15 Suppl):S435 -42. 
PROPRIETARY AND  CONFIDENTIAL  PAGE  75 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Mallamaci F, Testa A, Leonardis D, et al. A genetic marker of uric acid level, carotid 
atherosclerosis,  and arterial  stiffness:  a family -based  study.  Am J Kidney  Dis. 2015;65(2):294 - 
302. 
Peterson  DE, Oâ€™Shaughnessy  JA, Rugo  HS, et al.  Oral mucosal  injury  caused  by mammalian 
target  of rapamycin  inhibitors:  emerging  perspectives  on pathobiology  and impact  on clinical 
practice. Cancer Medicine. 2016; 5(8):1897 -1907.  
Rai SK, Avina -Zubieta  JA, McCormick  N, et al. Trends  in gout and rheumatoid  arthritis 
hospitalizations in Canada from 2000 -2011. Arthritis Care Res. 2017;69(5):758 -762. 
Richette  P, Garay  R. Novel  drug discovery  strategies  for gout.  Expert  Opin  Drug  Discov.  2013 
Feb;8(2):183 -9. 
Rock  KL, Kataoka  H, Lai JJ. Uric acid as a danger  signal  in gout and its comorbidities.  Nat Rev 
Rheumatol. 2013;9(1):13 -23. 
Ryan  LM. Gout.  http://www.merckmanuals.com/professional/musculoskeletal -and-connective - 
tissue -disorders/crystal -induced -arthritides/gout. Accessed July 22, 2016.  
Sampson HA, MuÃ±oz -Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum  A, et al. 
Second  symposium  on the definition  and management  of anaphylaxis:  summary  report --Second 
National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391 -7. 
So A. Developments  in the scientific  and clinical  understanding  of gout.  Arthritis  Res Ther. 
2008;10(5):221.  
Strand  V, Khanna  D, Singh  JA, Forsythe A,  Edwards  NL. Improved  health -related  quality  of life 
and physical function in patients with refractory chronic gout following treatment with 
pegloticase: evidence from phase III randomized controlled trials. J Rheumatol.  
2012;39(7):1450 -1457.  
 
Terkeltaub  R. Gout.  Novel  therapies  for treatment  of gout and hyperuricemia.  Arthritis  Res Ther. 
2009;11(4):236.  
Ware  JE Jr, Sherbourne  CD. The MOS  36-item short -form  health  survey  (SF-36). I. Conceptual 
framework and item selection. Med Care. 1992 Jun;30(6):473 -83. 
Woodworth T, Furst DE, Alten R, Bingham CO 3rd, Y ocum D, Sloan V, et al. Standardizing 
assessment  and reporting  of adverse  effects  in rheumatology  clinical  trials  II: the Rheumatology 
Common Toxicity Criteria v.2.0. J Rheumatol. 2007 Jun;34(6):1401 -14. 
PROPRIETARY AND  CONFIDENTIAL  PAGE  76 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Wortmann RL Gout and hyperuricemia. In Kelleyâ€™s Textbook of Rheumatology, 8th ed.; 
Firestein,  G.S; Budd,  R.C.;  Harris,  E.D.;  McInnes,  I.B; Ruddy,  S.; Sergent,  J.S. Eds.;  Elsevier: 
Philadelphia, 2008; pp 1481 -1506.  
Zhu Y, Pandya  BJ, Choi  HK. Comorbidities  of gout and hyperuricemia  in the US general 
population: NHANES 2007 -2008. Am J Med. 2012;125(7):679 -687.e671.  
World Medical Association. World Medical Association Declaration of Helsinki: ethical 
principles  for medical  research  involving  human  subjects.  JAMA.  2013  Nov 27;310(20):2191 -4. 
PROPRIETARY AND  CONFIDENTIAL  PAGE  77 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
20. APPENDICES  
APPENDIX  A SCHEDULE  OF ASSESSMENTS  FOR  PATIENTS  RANDOMIZED  TO SEL -212 
PROPRIETARY AND  CONFIDENTIAL  PAGE  78 OF 84  
  
Assessment  Scr. Treatment Period  (TP) EOS1 ET TP12 TP22 TP32 TP42 TP52 TP62 
Day - 45 d -7 d3 D0 D21 D04 D21 D04 D7 D14 D21 D04 D21 D04 D21 D04 D7 D14 D21 D2820   
Informed  Consent  X                     
Demographics  X                     
Inclusion/Exclusion  X                     
Medical  History  X                     
Physical  Examinations  X5  X6  X6  X6    X6  X6  X6    X5  X5 
Vital  Signs  X X X7  X7  X7    X7  X7  X7   X X  X 
Weight  and Heigh t8 X X  X  X    X  X  X    X X  X 
Tophus  Assessment  X                  X  X 
12-Lead  ECG  X                  X  X 
Screening  Labs9 X                     
Screening  Lab: Anti-PEG -Ab X                     
Urine  Pregnancy  Test X                     
Washout:  ULTs   X10 Patients  will abstain  from  ULT  use after the ULT  washout  period     
Document  ULTs  Discontinued   X                    
Dispense  Premedication:  Gout 
Flare and Infusion Reaction   
X                    
Premedication:  Gout  Flare   X11 Continuously     
Premedication:  Infusion 
Reaction    X12  X12  X12    X12  X12  X12       
Safety  Labs:  Chemistry13 X  X X  X    X  X  X    X X  X 
Safety  Labs:  Hematology14 X  X X  X    X  X  X    X X  X 
Safety  Labs:  Coagulation15 X  X X  X    X  X  X    X X  X 
Safety  Labs:  Lipids16 X  X X  X    X  X  X    X X  X 
Safety  Labs:  Urinalysis17 X  X X  X    X  X  X    X X  X 
Safety  Labs:  Anti-drug-Ab                   X  X 
Gout Flare  Assessment  X  X X X X X X X X X X X X X X X X X X X 
Joint  Assessment  (tenderness, 
swelling)    
X        
X        
X  
X  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 

Appendix  A SCHEDULE  OF ASSESSMENTS  FOR  PATIENTS  RANDOMIZED  TO SEL -212, CONTINUED  
PROPRIETARY AND  CONFIDENTIAL  PAGE  79 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 
 
Assessment  Scr. Treatment Period  (TP) EOS1 ET TP12 TP22 TP32 TP42 TP52 TP62 
Day - 45 d -7 d3 D0 D21 D04 D21 D04 D7 D14 D21 D04 D21 D04 D21 D04 D7 D14 D21 D2820   
Health Questionnaires18   X        X        X  X 
Collect Sample  for SUA  X  Refer  to Schedule  of Assessments  in Appendix  B for SUA  Sample  Collection  during  Treatment  Period   X 
Study  Drug  Administration    Refer  to Schedule  of Assessments  in Appendix  B for Study  Drug  Administration  during  the Treatment  Period    
Concomitant  Medications  / 
Procedures    Continuously  X X 
AE/SAE  Collection  X19 X19 Continuously  X X 
1. Phone  call at 30 (+ 4) days after the last study  drug infusion  for assessment  of concomitant  medications/procedures, AEs, and  SAEs.  
2. Visit  window at  Day 21 of each Treatment  Period  is -2 days to +1 day. 
3. Visit  window  is -2 days.  
4. Study  drug dosing  to occur  28 days from  the previous  dose with a window  of -4 days to +3 days of the intended  dosing  day. 
5. Full physical  exam  
6. Directed  physical  exam  
7. Assess  vital signs  on Day 0 at Time  0 (pre-dose),  within +  5 minutes after  completion  of infusion  of the first component  of study  drug,  and 1 hour (+  5 minutes) after  completion  of 
infusion of the second component of study drug.  
8. Height  measured  once  during  Screening  only.  
9. Screening  labs to include:  SUA,  anti-PEG -antibodies,  hepatitis  B and C antibodies,  human immunodeficiency  virus  1/2 (HIV1/2),  hemoglobin -A1c (HbA1c),  glucose, triglycerides, LDL, 
glucose -6-phosphate dehydrogenase (G6PD), WBC, AST, ALT, Hgb, serum creatinine, and serum phosphate, urinalys is 
10. Begin  ULT  washout  at least  7 days prior  to Day 0 of Treatment  Period  1. 
11. Begin  colchicine  0.6 mg QD  premedication at least  7 days prior  to Day 0 of Treatment  Period  1. Patients  not already  taking colchicine  will receive  colchicine  1.2 mg as a single loading 
dose followed  by the 0.6 mg every day regimen. If the patient cannot tolerate the loading dose level of  1.2 mg, then the patient will initiate and maintain colchicine at 0.6 mg.  
12. Pretreatment to  minimize  potential infusion reactions: oral  steroids  at 24 (Â±  12) hours  and oral antihistamines at  12 (Â± 2) hours and  2 (Â± 1) hours and IV  steroids  at 1 (Â± 0.5) hours  prior to 
study medication.  
13. Chemistry labs to  include:  Alkaline  phosphatase, alanine  aminotransferase  (ALT),  aspartate  aminotransferase  (AST),  total bilirubin,  blood  urea nitrogen  (BUN), creatinine,  fibrinogen, 
glucose (fasting), phosphorous, electrolytes (sodium, potassium, chloride, bi -carbonate, phosphate and magnesium).  
14. Hematology labs to  include: white  blood  cells (WBC)  count  with differential, red  blood  cell (RBC)  count,  hematocrit (Hct),  hemoglobin  (Hgb),  mean corpuscular  volume (MCV),  mean 
corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW),  platelet (Plt) count, mean platelet volume (MPV)  
15. Coagulation  labs to include:  prothrombin  time (PT),  activated  partial  thromboplastin  time (aPTT),  international  normalized  ratio (INR)  
16. Lipid  labs to include:  total cholesterol,  HDL,  LDL,  triglycerides  
17. Urinalysis  to include:  urinary  protein,  albumin, creatinine,  pH, specific  gravity,  blood,  glucose,  ketones,  bilirubin,  leukocyte, esterase,  WBC,  RBC,  crystals,  casts  (cast types),  epithelial 
cells (renal and nonrenal), bacteria, mucus, and ye ast. 
18. Refer  to Section  11.3 for Health  Questionnaires.  
19. During  Screening,  SAE  collection  begins at  time of signing  informed  consent. Non -serious AE  will not be collected  during  Screening.  
20. Visit  window  is -2 days to +6 days 
Abbreviations:  Ab: antibody; D  (d): day; ECG:  electrocardiogram;  EOS:  end of study;  ET: early  termination;  h: hour;  RCTC:  Rheumatology  Common  Toxicity  Criteria;  Scr: 
Screening Period; SUA: serum uric acid; TP: treatment period; ULT: urate lowering therapy  
APPENDIX  B SCHEDULE  OF ASSESSMENTS:  SEL -212 DOSING  AND  SUA  DURING  THE  TREATMENT  PERIOD  
PROPRIETARY AND  CONFIDENTIAL  PAGE  80 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 
 
Assessments  
Day 
Timepoint  Treatment  Periods:  1, 2, 4, and 5 Treatment  Periods  3 and  6 
D01 D21 D01 D7 D14 D21 D282 
0h ~1.5h  ~3.5h  ~4.5h   0h ~1.5h  ~3.5 ~4.5h      
Premedicate:  Infusion  Reaction  X3     X        
Blood  Sample: SUA  X4   X5 X X4   X5 X X X X 
Study  Drug  Infusion  (Component  1)6 X -----------  7    X ------------  7       
Study  Drug  Infusion  (Component  2)8  X7 -------------  X    X7 -------------  X      
1. Study  drug dosing  to occur  28 days from  the previous  dose with a window  of -4 days to +3 days  of the intended  dosing  day. 
2. Treatment  Period  6 only.  
3. Pretreatment  to minimize  potential  infusion  reactions: oral  steroids  at 24 (Â± 12) hours  and oral  antihistamines  at 12 (Â± 2) hours  and 2 (Â± 1) hours  and IV steroids  at 1 (Â± 0.5) 
hours prior to study medication.  
4. Obtain  sample  prior  to study  drug infusion.  
5. Obtain  sample  1 (Â± 0.25)  hour after completion  of infusion  of Component  2. 
6. Component  1 will be SEL-110.36  for patients  randomized  to treatment  with SEL-212. 
7. Before  starting  infusion  with Component  2, a period  of up to 15 minutes  is permitted  after completion  of infusion  of Component  1. 
8. Component  2 will be SEL-037 for patients  randomized  to treatment  with SEL-212. 
PROPRIETARY AND  CONFIDENTIAL  PAGE  81 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
APPENDIX  C SCHEDULE  OF ASSESSMENTS  FOR  PATIENTS  RANDOMIZED  TO KRYSTEXXA  
 
Assessment  Scr. Treatment Period  (TP) EOS1 ET TP12 TP22 TP32 TP42 TP52 TP62 
Day - 45 d -7 d3 D0 D14 D04 D14 D04 D7 D14 D21 D04 D14 D04 D14 D04 D7 D14 D21 D2820   
Informed  Consent  X                     
Demographics  X                     
Inclusion/Exclusion  X                     
Medical  History  X                     
Physical  Examinations  X5  X6  X6  X6    X6  X6  X6    X5  X5 
Vital  Signs  X X X7 X7 X7 X7 X7  X7  X7 X7 X7 X7 X7  X7 X X  X 
Weight  and Heigh t8 X X  X  X   X   X  X   X  X  X 
Tophus  Assessment  X                  X  X 
12-Lead  ECG  X                  X  X 
Screening  Labs9 X                     
Screening  Lab: Anti-PEG -Ab X                     
Urine  Pregnancy  Test X                     
Washout:  ULTs   X10 Patients  will abstain  from  ULT  use after the ULT  washout  period     
Document  ULTs  Discontinued   X                    
Dispense  Premedication:  Gout 
Flare and Infusion Reaction   
X                    
Premedication:  Gout  Flare   X11 Continuously     
Premedication:  Infusion 
Reaction    X12 X12 X12 X12 X12  X12  X12 X12 X12 X12 X12  X12     
Safety  Labs:  Chemistry13 X  X X  X   X   X  X   X  X  X 
Safety  Labs:  Hematology14 X  X X  X   X   X  X   X  X  X 
Safety  Labs:  Coagulation15 X  X X  X   X   X  X   X  X  X 
Safety  Labs:  Lipids16 X  X X  X   X   X  X   X  X  X 
Safety  Labs:  Urinalysis17 X  X X  X   X   X  X   X  X  X 
Safety  Labs:  Anti-drug-Ab                   X  X 
Gout  Flare  Assessment  X  X X X X X X X X X X X X X X X X X X X 
Joint  Assessment  (tenderness, 
swelling)    
X        
X        
X  
X 
Health Questionnaires18   X        X        X  X 
PROPRIETARY AND  CONFIDENTIAL  PAGE  82 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
Appendix  C, SCHEDULE  OF ASSESSMENTS  FOR  PATIENTS  RANDOMIZED  TO KRYSTEXXA,  CONTINUED  
 
Assessment  Scr. Treatment Period  (TP) EOS1 ET TP12 TP22 TP32 TP42 TP52 TP62 
Day - 45 d -7 d3 D0 D14 D04 D14 D04 D7 D14 D21 D04 D14 D04 D14 D04 D7 D14 D21 D2820   
Collect Sample  for SUA  X  Refer  to Schedule  of Assessments  in Appendix  D for SUA  Sample  Collection  during  Treatment  Period   X 
Study  Drug Administration    Refer  to Schedule  of Assessments  in Appendix  D for Study  Drug  Administration  during  the Treatment  Period    
Concomitant  Medications  / 
Procedures    
Continuously  X X 
AE/SAE  Collection  X19 X19 Continuously  X X 
 
1. Phone  call at 30 (+ 4) days after the last study  drug infusion  for assessment  of concomitant  medications/procedures, AEs, and  SAEs.  
2. Visit  window at  Day 14 of each Treatment  Period  is -2 days to +3 days;  visit window  at Day 7 and 21 of TP3 and TP6 is -2 days to  +3 days.  
3. Visit  window  is -2 days.  
4. Study  drug dosing  to occur  14 days from  the previous  dose with a window  of -2 days to +3 days of the intended  dosing  day. 
5. Full physical  exam  
6. Directed  physical  exam  
7. Assess  vital signs  on Day 0 and 14 at Time  0 (pre-dose),  and 1 hour (+ 5 minutes)  after completion  of infusion.  
8. Height  measured  once  during  Screening  only.  
9. Screening  labs to include:  SUA,  anti-PEG -antibodies,  hepatitis  B and C antibodies,  human immunodeficiency  virus  1/2 (HIV1/2),  hemoglobin -A1c (HbA1c),  glucose, triglycerides, LDL, 
glucose -6-phosphate dehydrogenase (G6PD), WBC, AST, ALT, Hgb, serum creatinine, and serum phosphate  
10. Begin  ULT  washout  at least  7 days prior  to Day 0 of Treatment  Period  1. 
11. Begin  colchicine  0.6 mg QD  premedication at least  7 days prior  to Day 0 of Treatment  Period  1. Patients  not already  taking colchicine  will receive  colchicine  1.2 mg  as a single loading 
dose followed  by the 0.6 mg every day  regimen. If the patient cannot tolerate the loading dose level of  1.2 mg, then the patient will initiate and maintain colchicine at 0.6 mg.  
12. Pretreatment to  minimize  potential infusion reactions: oral  steroids  at 24 (Â±  12) hours  and oral antihistamines at  12 (Â± 2) hours and  2 (Â± 1) hours and IV  steroids  at 1 (Â± 0.5) hours  prior to 
study medication.  
13. Chemistry labs to  include:  Alkaline  phosphatase, alanine  aminotransferase  (ALT),  aspartate  aminotransferase  (AST),  total bilirubin,  blood  urea nitrogen  (BUN), creatinine,  fibrinogen, 
glucose (fasting), phosphorous, electrolytes (sodium, potassium, chloride, bi -carbonate, phosphate and magnesium).  
14. Hematology labs to  include:  white  blood  cells (WBC)  count with  differential, red  blood  cell (RBC)  count,  hemat ocrit (Hct),  hemoglobin  (Hgb),  mean corpuscular  volume (MCV),  mean 
corpuscular hemoglobin (MCH), mean corpuscular  hemoglobin concentration (MCHC), red cell distribution width (RDW),  platelet (Plt) count, mean platelet volume (MPV)  
15. Coagulation  labs to include:  prothrombin  time (PT),  activated  partial  thromboplastin  time (aPTT),  international  normalized  ratio (INR)  
16. Lipid  labs to include:  total cholesterol,  HDL,  LDL,  triglycerides  
17. Urinalysis  to include:  urinary  protein,  albumin, creatinine,  pH, specific  gravity,  blood,  glucose,  ketones,  bilirubin,  leukocyte, esterase,  WBC,  RBC,  crystals,  casts  (cast types),  epithelial 
cells (renal and nonrenal), bacteria, mucus, and yeast.  
18. Refer  to Section  11.3 for Health  Questionnaires.  
19. During  Screening,  SAE  collection  begins  at time of signing  informed  consent.  Non-serious AE  will not be collected  during  Screening.  
20. Visit  window  is -2 days to +6 days 
Abbreviations:  Ab: antibody; D  (d): day; ECG:  electrocardiogram;  EOS:  end of study;  ET: early  termination;  h: hour;  RCTC:  Rheumatology  Common  Toxicity  Criteria;  Scr: 
Screening Period; SUA: serum uric acid; TP: treatment period; ULT: urate lowering therapy  
PROPRIETARY AND  CONFIDENTIAL  PAGE  83 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
  
 
 
APPENDIX D  SCHEDULE  OF ASSESSMENTS:  KRYSTEXXA  DOSING  AND  SUA  DURING  THE  TREATMENT 
PERIOD  
 
Assessments  
Day 
Timepoint  Treatment  Periods:  1, 2, 4, and 5 Treatment  Periods  3 and  6 
D01 D14 D01 D7 D14 D21 D282 
0h ~2.0h  ~3.0h  0h ~2.0h  ~3.0h  0h ~2.0h  ~3.0h   0h ~2.0h  ~3.0h    
Premedicate:  Infusion  Reaction  X3   X3   X    X3     
Blood  Sample: SUA  X4  X5 X4  X5 X4  X5 X X4  X5 X X 
Study  Drug  Infusion  X ---------  X  X ---------  X  X ----------  X   X ---------  X    
1. Study  drug dosing  to occur  14 days from  the previous  dose with a window  of -2 days to +3 days  of the intended  dosing  day. 
2. Treatment  Period  6 only.  
3. Pretreatment  to minimize  potential  infusion  reactions: oral  steroids  at 24 (Â± 12) hours  and oral  antihistamines  at 12 (Â± 2) hours  and 2 (Â± 1) hours  and IV steroids  at 1 (Â± 0.5) 
hours prior to study medication.  
4. Obtain  sample  prior  to study  drug infusion.  
5. Obtain  sample  1 (Â± 0.25)  hour after completion  of infusion.  
PROPRIETARY AND  CONFIDENTIAL  PAGE  84 OF 84  
  STUDY : SEL-212/202 
VERSION : 3.0 EFFECTIVE  DATE  
08 JUN 2020  
 
Revision  History  
 
Version  Reason  for Change  Date  
1.1 â€¢ Clarifications,  administrative  corrections  12 APR  2019  
2.0 â€¢ Clarifications,  administrative  corrections  
â€¢ Updated  study personnel  information  
â€¢ Reduced Screening threshold SUA to 7 mg/dL to allow 
for enrollment  of all patients  with serum  uric acid above 
the limit of solubility  14 MAY  2019  
2.1 â€¢ Clarifications,  administrative  corrections  
â€¢ Updated  study  personnel  information  
â€¢ Added  oral steroid  premedication  24hr prior  to dose 03 FEB 2020  
3.0 â€¢ Clarifications,  administrative  corrections  
â€¢ Updated  study  personnel  information  and sponsor  address  
â€¢ Updated  secondary endpoints  
â€¢ Updated  statistical  analysis  population  definitions  
â€¢ Updated  primary  efficacy  population  to be  ITT 
â€¢ Updated  statistical  analysis  approach  for gout flare 
endpoint  
â€¢ Clarification  of visit  windows  08 JUN 2020  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
